Multi-kinase inhibitors, compositions and methods of use thereof
By developing multi-kinase inhibitors targeting HPK1, FLT3, and Aurora kinase, the problem of insignificant efficacy of single-molecule therapy in existing technologies has been solved, enabling effective treatment of various cancers, especially solid tumors and hematological cancers.
Patent Information
- Application Number
- CN202380034233.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-20
- Filing Date
- 2023-06-05
- Publication Date
- 2024-11-26
AI Technical Summary
Existing technologies have difficulty effectively targeting protein kinases in multiple key signal transduction pathways, resulting in limited efficacy of single-molecule therapy in cancer treatment, especially with insignificant inhibitory effects on hematopoietic progenitor cell kinase 1 (HPK1), human Fms-like tyrosine kinase 3 receptor (FLT3), and aurora kinase.
A multi-kinase inhibitor that simultaneously targets HPK1, FLT3, and aurora kinase has been developed, comprising compounds with specific structures and their tautomers and deuterated derivatives, for use in preparing pharmaceutical compositions to treat related diseases.
By simultaneously inhibiting multiple kinases, it enhances the therapeutic effect on a variety of cancers, including solid tumors and hematologic malignancies, improving the significance of treatment and the ability to overcome drug resistance.
Smart Images

Figure CN119032093A_ABST
Abstract
Description
[0001] Inventors: Tianwei Ma, Lichao Fang, Miao Liu and Ling Song. Field of the Invention
[0002] The present disclosure provides compounds of formula I, their tautomers, deuterated derivatives of the compounds or the tautomers, and pharmaceutically acceptable salts of the aforementioned compounds; compositions comprising compounds of formula I, their tautomers, deuterated derivatives of the compounds or the tautomers, and / or pharmaceutically acceptable salts of the aforementioned compounds; and methods of using the above substances to treat diseases, disorders or conditions mediated by inhibition of protein kinases (such as hematopoietic progenitor cell kinase 1 (HPK1, MAP4K1), human Fms-like tyrosine kinase 3 receptor (FLT3) and Aurora kinases). Background of the Invention
[0004] Protein kinases are enzymes that catalyze the phosphorylation of hydroxyl groups on tyrosine, serine, and threonine residues in proteins. Protein kinases play a key role in signal transduction for a variety of cellular functions, including cell cycle, metabolism, carcinogenesis, differentiation, proliferation, and apoptosis. In addition, dysregulated protein kinases are associated with a large number of pathologies, including immune, tumor, metabolic, neurological, and infectious diseases. Many protein kinases are particularly dysregulated during tumorigenesis. Therefore, protein kinases are interesting targets for anticancer drugs.
[0005] Serine / threonine kinases are an important class of protein kinases that are specific for phosphorylation of serine and threonine residues. Another major class of protein kinases is tyrosine kinases, which are specific for phosphorylation of tyrosine residues. There are also some dual-specificity kinases that can phosphorylate both tyrosine and serine / threonine residues (Expert Rev Anticancer Ther, 2018, 18(12): 1249-1270).
[0006] Hematopoietic progenitor cell kinase 1 (HPK1, MAP4K1) is a serine / threonine kinase and a member of the MAP4K family. HPK1 is primarily expressed in hematopoietic cell lines and is a negative regulator of T lymphocyte and dendritic cell activation. Therefore, HPK1 inhibition is expected to prolong T cell activation and enhance the APC function of dendritic cells. Therefore, HPK1 has been identified as a novel anticancer immunotherapy and a new intracellular checkpoint molecule, as well as a potential combination therapy with current checkpoint molecules. In addition to inhibiting its kinase activity, degraders that target HPK1 for degradation can also eliminate the potential scaffold function of HPK1, thereby overcoming drug resistance.
[0007] Aurora kinases are a family of highly conserved serine / threonine kinases that are important for the fidelity transition to mitosis. Aurora kinase A plays an important role in centrosome maturation, spindle assembly, meiotic maturation, and metaphase I spindle positioning and has been found to be overexpressed in a variety of human cancers (Front Oncol, 2015, 5: 278). Due to the overexpression of Aurora kinases and their association with genetic instability and aneuploidy in tumors, a variety of cancers, including acute myeloid leukemia (AML), have been responsive to Aurora kinase inhibitors. Although different Aurora kinase inhibitors have been tested in clinical trials, limited efficacy has been observed. Therefore, novel Aurora kinase inhibitors may be a strategy to significantly improve clinical efficacy and overcome drug resistance.
[0008] Human Fms-like tyrosine kinase 3 receptor (FLT3), or fetal liver kinase 2 (FLK-2), CD135, is a member of the type III receptor tyrosine kinase. FLT3 is overexpressed in about 90% of acute myeloid leukemia (AML), most acute lymphocytic leukemia (ALL), and blast crisis chronic myeloid leukemia (BC-CML). FLT3 is one of the most commonly mutated genes in hematological malignancies. FLT3 mutations have been found in 1-3% of ALL patients, 5-10% of myelodysplasia patients, and 15-35% of AML patients. FLT3 mutations can be subdivided into internal tandem duplications (ITD), which are present in about 25% of patients; and point mutations in the tyrosine kinase domain (TKD) (such as D835 and I836), which are present in about 5% of patients. Both FLT3-ITD mutations and FLT3-TKD mutations are constitutively active, resulting in ligand-independent FLT3 signaling and cell proliferation (Front Oncol, 2020; 10: 612880). Current small molecule FLT3 inhibitors do not bring significant clinical efficacy as monotherapy. It is necessary to provide alternative FLT3 inhibitors to induce rapid downregulation of downstream kinases of the FLT3 and STAT5 pathways in leukemia patients.
[0009] In malignant tumors, there are always multiple kinase abnormalities and multiple signal transduction pathway dysregulations. More importantly, a single molecule abnormality may also cause multiple downstream effects. Therefore, compared with single targeted therapy, multi-targeted therapy using a single molecule (multiple kinase inhibitors or degraders) to simultaneously target multiple kinases and multiple signal transduction pathways is more ideal.
[0010] Therefore, the present disclosure aims to provide compounds that simultaneously target several key signal transduction pathways.
[0011] In view of the importance of the above protein kinases in tumorigenesis, multi-kinase inhibitors can be used as a single agent or in combination to treat solid tumors, including but not limited to: brain cancer, breast cancer, respiratory tract and / or lung cancer, reproductive organ cancer, bone cancer, digestive tract cancer, urethral cancer, eye cancer, liver cancer, skin cancer, head and neck cancer, anal cancer, nervous system cancer, thyroid cancer, parathyroid cancer. For example, multi-kinase inhibitors can be used as a single agent or in combination to treat blood cancers, including but not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and myelodysplastic syndrome (MDS). SUMMARY OF THE INVENTION
[0013] One aspect of the present disclosure provides a compound selected from Formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing compound, which can be used to treat diseases mediated by protein kinase inhibition, such as hematopoietic progenitor kinase 1 (HPK1, MAP4K1), human Fms-like tyrosine kinase 3 receptor (FLT3) and Aurora kinase. For example, disclosed herein is a compound with a structure as shown in Formula I:
[0014]
[0015] Its tautomer, the deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the aforementioned compound, wherein:
[0016] (i)R 1 and R 2 independently selected from the group consisting of linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, linear alkenyl, branched alkenyl, cycloalkenyl, linear heteroalkenyl, branched heteroalkenyl, heteroalkenyl, linear alkynyl, branched alkynyl, cycloalkynyl, CO2R x 、C(O)NR x R y 、C(O)R x OR y 、C(O)R w N(R x R y )2、OC(O)R w NR x R y 、S(O)R y and SO2R y ;
[0017] (ii) R 3 Selected from: hydrogen, halogen groups, OR x , SR x 、NHR x 、N(R x 2. CHR x and C(R x )2;
[0018] (iii) R 4 Selected from: hydrogen, straight chain alkyl, branched chain alkyl, cycloalkyl, heterocyclic group, C(O)R y 、CO2R y 、C(O)R w OR y 、C(O)R w N(R x R y )2、OC(O)R w NR x R y , R w N(R x R y 2. R w OR x , R z R'、S(O)R y and SO2R y ;
[0019] (iv) R x and R y R is independently selected from the group consisting of hydrogen, linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl; or x and R y are linked to each other to form an optionally substituted heterocycloalkyl group;
[0020] (v)R w is absent or is selected from the group consisting of: straight chain alkyl, branched chain alkyl, cycloalkyl, carbocyclyl, heterocyclyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, straight chain heteroalkenyl, and branched chain heteroalkenyl;
[0021] (vi)R z Not present or selected from: linear alkyl, branched alkyl and cycloalkyl;
[0022] (vii) R' is selected from the group consisting of optionally substituted heteroaryl and optionally substituted heterocycloalkyl;
[0023] (viii) Ring A is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and
[0024] (ix) Ring B is selected from:
[0025] (x) wherein each R" is independently selected from: hydrogen, linear alkyl, branched alkyl and cycloalkyl; or two R" combine to form a cycloalkyl spiro ring or a heterocycloalkyl spiro ring;
[0026] wherein the straight chain alkyl, branched chain alkyl, cycloalkyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, carbocyclyl, branched chain heteroalkenyl, branched chain heteroalkenyl, straight chain alkynyl, branched chain alkynyl, cycloalkynyl, heterocyclyl, aryl and heteroaryl are optionally substituted by at least one group selected from the following groups:
[0027] Halogen groups,
[0028] Hydroxyl,
[0029] Thiols,
[0030] Amino,
[0031] Cyano,
[0032] -OC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0033] -C(O)OC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0034] -NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0035] -N(C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl)2,
[0036] -NHC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0037] -C(O)NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0038] -NH aryl,
[0039] -N(aryl)2,
[0040] -NHC(O)aryl,
[0041] -C(O)NHaryl,
[0042] -NH heteroaryl,
[0043] -N(heteroaryl)2,
[0044] -NHC(O)heteroaryl,
[0045] -C(O)NHheteroaryl,
[0046] C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0047] C2-C6 straight-chain alkenyl, branched-chain alkenyl and cycloalkenyl,
[0048] C1-C6 straight chain hydroxyalkyl, branched chain hydroxyalkyl and cyclic hydroxyalkyl,
[0049] C1-C6 straight-chain aminoalkyl, branched-chain aminoalkyl and cyclic aminoalkyl,
[0050] C1-C6 straight chain alkoxy, branched chain alkoxy and cycloalkoxy,
[0051] C1-C6 straight chain sulfanyl, branched chain sulfanyl and cyclic sulfanyl,
[0052] C1-C6 straight chain haloalkyl, branched chain haloalkyl and cyclic haloalkyl,
[0053] C1-C6 straight chain halogenated aminoalkyl, branched chain halogenated aminoalkyl and cyclic halogenated aminoalkyl,
[0054] C1-C6 straight chain halosulfanyl, branched chain halosulfanyl and cyclic halosulfanyl,
[0055] C1-C6 straight chain halogenated oxyalkyl, branched chain halogenated oxyalkyl and cyclic halogenated oxyalkyl,
[0056] benzyloxy, benzylamino and benzylthio,
[0057] 3-6 membered heterocycloalkenyl, 3-6 membered heterocyclyl, 3-6 membered spirocycloalkyl, 3-6 membered spiroheterocyclyl, and
[0058] 5-membered heteroaryl and 6-membered heteroaryl, which are optionally substituted with 0, 1 or 2 C1-C6 alkyl groups selected from the group consisting of linear alkyl, branched alkyl and cycloalkyl.
[0059] In one aspect of the present disclosure, the compound of formula I is selected from: compounds 1-14 shown below, tautomers thereof, deuterated derivatives of the compounds or the tautomers, and pharmaceutically acceptable salts of the foregoing compounds.
[0060] In some embodiments, the present disclosure provides a pharmaceutical composition comprising: a compound of formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the aforementioned compound, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises: a compound selected from compounds 1-14 as shown below, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the aforementioned compound. The composition may further comprise an additional active agent.
[0061] Another aspect of the present disclosure provides a method for treating a disease, disorder or condition mediated by protein kinase inhibition in a subject, comprising administering a therapeutically effective amount of a compound of formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing compound, or a pharmaceutical composition comprising any of the foregoing. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a compound selected from compounds 1-14 as shown below, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing compound, or a pharmaceutical composition comprising any of the foregoing compounds.
[0062] In some embodiments disclosed herein, the treatment method includes administering an additional active agent to a subject in need thereof, which may be in the same pharmaceutical composition as the compound of Formula I, its tautomer, the deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing compound, or in a separate composition. In some embodiments disclosed herein, the treatment method includes administering a compound selected from Compounds 1-14 shown below, its tautomer, the deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing compound, and an additional active agent in the same composition or in a separate composition.
[0063] Also disclosed herein is a method for inhibiting protein kinase activity, comprising administering to a subject a therapeutically effective amount of a compound of formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing compound, or a pharmaceutical composition comprising any of the foregoing compounds. In some embodiments disclosed herein, the method for inhibiting protein kinase comprises administering to a subject a compound selected from compounds 1-14 shown below, a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing compound, or a pharmaceutical composition comprising any of the foregoing compounds. In some embodiments, the method for inhibiting protein kinase activity comprises contacting the protein kinase with a compound of formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing compound, or a pharmaceutical composition comprising any of the foregoing compounds. In some embodiments disclosed herein, the method of inhibiting a protein comprises contacting a protein kinase with a compound selected from compounds 1-14 shown below, a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing compound, or a pharmaceutical composition comprising any of the foregoing compounds. DETAILED DESCRIPTION OF THE INVENTION
[0065] I. Definitions
[0066] The term "a / an" herein includes the expression "at least one / one" when referring to a noun, and thus includes both the singular unit and the plural unit of the noun. For example, "an additional pharmaceutical agent" refers to one or two or more additional pharmaceutical agents.
[0067] The term "protein kinase" is an enzyme that catalyzes the phosphorylation of hydroxy groups on tyrosine, serine and threonine residues in proteins. Serine / threonine kinases are specific for the phosphorylation of serine and threonine residues and constitute an important family of protein kinases. Another major family of protein kinases is the tyrosine kinases, which are specific for the phosphorylation of tyrosine residues. In addition, there are dual specificity kinases, which can simultaneously phosphorylate tyrosine and serine / threonine residues. Examples of protein kinases include, but are not limited to, hematopoietic progenitor cell kinases, mitogen-activated protein kinases 1 / 2, human Fms-like tyrosine kinase 3 and aurora kinases.
[0068] As used herein, the term "HPK1" or "hematopoietic progenitor cell kinase 1", also known as MAP4K1, is a serine / threonine kinase that is primarily expressed in hematopoietic cells, such as T cells, B cells, and dendritic cells (DCs). HPK1 is involved in regulating various downstream signaling pathways, such as extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and nuclear factor-κB (NF-κB), all of which are involved in the regulation of cell proliferation and immune cell activation.
[0069] As used herein, the term "FLT3" or "human Fms-like tyrosine kinase 3 receptor", also known as fetal liver kinase 2 (FLK-2) or CD135, is a member of the type III receptor tyrosine kinase. FLT3 is overexpressed in approximately 90% of acute myeloid leukemia (AML), most acute lymphocytic leukemia (ALL), and blast crisis chronic myeloid leukemia (BC-CML). FLT3 is one of the most commonly mutated genes in hematological malignancies. FLT3 mutations have been found in 1%-3% of ALL patients, 5%-10% of myelodysplasia patients, and 15%-35% of AML patients. FLT3 mutations can be subdivided into: internal tandem duplications (ITD), accounting for approximately 25% of patients; and point mutations (such as D835 and I836) in the tyrosine kinase domain (TKD), accounting for approximately 5% of patients. Both FLT3-ITD and FLT3-TKD mutations are constitutively active, resulting in ligand-independent FLT3 signaling and cell proliferation.
[0070] As used herein, the term "Aurora kinase" is a key cell cycle regulator that is involved in the pathogenesis of multiple tumor types. In humans, there are three isoforms of Aurora kinase: Aurora kinase A, Aurora kinase B, and Aurora kinase C. Aurora kinase A and Aurora kinase B play key roles in mitosis, while the activity of Aurora kinase C is primarily restricted to meiotic cells. Aurora kinase A and Aurora kinase B are closely related in structure, but their roles in mitosis are quite different. The Aurora kinase A gene (AURKA) is located on chromosome 20ql3.2 and is frequently amplified or overexpressed in a variety of cancers. The encoded protein is present at the centrosomes of interphase cells and at the spindle poles in mitosis. Aurora kinase A interacts with and phosphorylates a variety of proteins that together function to regulate mitotic progression and cell division. Aurora kinase A is functionally associated with a variety of tumor suppressors and oncogenes. It promotes transcription of the c-Myc oncogene and protects the N-Myc protein from ubiquitination and subsequent degradation. It also downregulates p53 and inhibits the function of BRCA1 / 2 tumor suppressors. Overexpression of Aurora kinase A results in a dysregulated chemical balance between Aurora kinase A and its interacting partners, leading to oncogenic transformation. The potential oncogenic role of Aurora kinase A has generated a great deal of interest in targeting this kinase to treat cancers caused by genetic instability, aneuploidy, or genetic alterations in oncogenes (e.g., Myc, RAS, PKA) or tumor suppressors (e.g., TP53, BRCA1 / 2).
[0071] The compounds disclosed herein can inhibit protein kinases. Therefore, the compounds disclosed herein are generally useful for treating diseases or conditions associated with such kinases. In one embodiment, the compounds disclosed herein are HPK1 inhibitors, FLT3 inhibitors, or Aurora kinase A inhibitors, which can be used to treat diseases associated with such kinases, such as cancer.
[0072] As used herein, the term "inhibitor" refers to a molecule that inhibits kinase activity, such as HPK1, FLT3, and Aurora kinase A. "Inhibition" herein refers to a reduction in the activity of the target enzyme compared to when the inhibitor is not present. For example, in some embodiments, the term "inhibition" refers to a reduction in HPK1 activity of at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%. In other embodiments, inhibition refers to a reduction in HPK1 activity of about 5% to about 25%, about 25% to about 50%, about 50% to about 75%, or about 75% to 100%. In some embodiments, inhibition refers to a reduction in HPK1 activity of about 95% to 100%, for example, a reduction in activity of 95%, 96%, 97%, 98%, 99%, or 100%. This reduction can be measured using various techniques that can be recognized by those skilled in the art, including in vitro kinase assays.
[0073] As used herein, the term "protein kinase inhibitor" or "protein kinase antagonist" is a molecule that reduces, inhibits or otherwise attenuates one or more biological activities of a protein kinase, such as HPK1, FLT3, and Aurora kinase A. The inhibitory effect of a protein kinase inhibitor does not necessarily mean that the protein kinase activity is completely eliminated. Instead, the activity of the protein kinase may be reduced by a statistically significant amount, including, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95% or 100% compared to an appropriate control. For example, in some embodiments, a protein kinase inhibitor may reduce, inhibit or otherwise attenuate the serine / threonine kinase activity of HPK1. In some of these embodiments, a protein kinase inhibitor may reduce, inhibit or otherwise attenuate the phosphorylation of SLP76 and / or Gads mediated by a protein kinase. The presently disclosed compounds can directly bind to protein kinases and inhibit their kinase activity.
[0074] The term "compound" when referring to a compound of the present disclosure refers to a collection of molecules having the same chemical structure, unless otherwise expressed as a collection of stereoisomers (e.g., a collection of racemates, a collection of cis / trans stereoisomers, or a collection of (E) and (Z) stereoisomers), but there may be isotopic differences between the constituent atoms of the molecules. Therefore, it can be clearly seen by those skilled in the art that a compound represented by a specific chemical structure containing a specified deuterium atom will also contain a smaller amount of isotopologues having hydrogen atoms at one or more specified deuterium positions in the structure. The relative content of such isotopologues in the compounds of the present disclosure depends on a variety of factors, including, for example, the isotopic purity of the reagents used to make the compound, and the incorporation efficiency of the isotopes in the various synthetic steps used to prepare the compound. However, as described above, the relative content of these isotopologues will generally be less than 49.9% of the compound. In other embodiments, the relative total amount of such isotopologues will be less than 47.5%, less than 40%, less than 32.5%, less than 25%, less than 17.5%, less than 10%, less than 5%, less than 3%, less than 1% or less than 0.5% of the compound.
[0075] As used herein, "optionally substituted" is interchangeable with "substituted or unsubstituted." In general, the term "substituted" refers to the replacement of hydrogen radicals in a given structure with the group of a specified substituent. Unless otherwise specified, an "optionally substituted" group may have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from the specified group, the substituent at each position may be the same or different. Combinations of substituents contemplated by the present disclosure are those combinations that form stable or chemically feasible compounds.
[0076] The term "isotopologue" refers to substances that differ in chemical structure only in isotopic composition. In addition, unless otherwise specified, structures described herein also include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, in addition to the replacement of hydrogen by deuterium or tritium, or carbon by 13 C or 14 C substitution, compounds having this structure are within the scope of the present disclosure.
[0077] Unless otherwise stated, structures described herein also include all isomers of the structure, such as racemic mixtures, cis / trans isomers, geometric (or conformational) isomers, such as (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, geometric mixtures and conformational mixtures of the compounds are within the scope of the present disclosure. Unless otherwise stated, all tautomers of the compounds of the present disclosure are within the scope of the present disclosure.
[0078] As used herein, the term "tautomer" refers to one of two or more isomers of a compound that coexist in equilibrium and that are easily interchangeable by migration of atoms (such as hydrogen atoms) or groups within the molecule.
[0079] As used herein, "stereoisomers" refers to both enantiomers and diastereomers.
[0080] As used herein, a "deuterated derivative" refers to a compound having the same chemical structure as a reference compound, but in which one or more hydrogen atoms have been replaced by a deuterium atom ("D" or "2H"). It will be appreciated that the natural isotopic abundance in a synthetic compound will vary somewhat depending on the source of the chemical materials used in the synthesis. Despite this variation, the concentration of the naturally abundant, stable hydrogen isotope is small and insignificant compared to the extent of stable isotopic substitution in the deuterated derivatives disclosed herein. Therefore, unless otherwise indicated, when referring to a "deuterated derivative" of a compound of the present disclosure, at least one hydrogen has been replaced by deuterium, and the deuterium content is much higher than its natural isotopic abundance, typically about 0.015%. In some embodiments, the deuterated derivatives disclosed herein have an isotopic enrichment factor per deuterium atom of at least 3500 (52.5% deuterium incorporation per designated deuterium atom), at least 4500 (67.5% deuterium incorporation per designated deuterium atom), at least 5000 (75% deuterium incorporation per designated deuterium atom), at least 5500 (82.5% deuterium incorporation per designated deuterium atom), at least 6000 (90% deuterium incorporation per designated deuterium atom), at least 6333.3 (95% deuterium incorporation per designated deuterium atom), at least 6466.7 (97% deuterium incorporation per designated deuterium) or at least 6600 (99% deuterium incorporation per designated deuterium).
[0081] As used herein, the term "isotopic enrichment factor" refers to the ratio of the isotopic abundance to the natural abundance of a particular isotope.
[0082] As used herein, the term "alkyl" refers to a fully saturated straight or branched, substituted or unsubstituted hydrocarbon chain. Unless otherwise specified, the alkyl group contains 1-30 alkyl carbon atoms. In some embodiments, the alkyl group contains 1-20 alkyl carbon atoms. In some embodiments, the alkyl group contains 1-10 alkyl carbon atoms. In some embodiments, the alkyl group contains 1-8 aliphatic carbon atoms. In some embodiments, the alkyl group contains 1-6 alkyl carbon atoms. In some embodiments, the alkyl group contains 1-4 alkyl carbon atoms. In other embodiments, the alkyl group contains 1-3 alkyl carbon atoms. And in other embodiments, the alkyl group contains 1-2 alkyl carbon atoms. In some embodiments, the alkyl group is substituted. In some embodiments, the alkyl group is unsubstituted. In some embodiments, the alkyl group is linear or straight chain or unbranched. In some embodiments, the alkyl group is branched.
[0083] The term "cycloalkyl" refers to a fully saturated monocyclic C 3-8 hydrocarbon or spirocyclic, fused or bridged bicyclic or tricyclic C 8-14 In some embodiments, the cycloalkyl group is substituted. In some embodiments, the cycloalkyl group is unsubstituted. In some embodiments, the cycloalkyl group is C 3-12 In some embodiments, the cycloalkyl group is C 3-8 In some embodiments, the cycloalkyl group is C 3-6 Cycloalkyl. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0084] The term "carbocyclyl" encompasses the term "cycloalkyl" and refers to a fully saturated monocyclic C 3-8 Hydrocarbon or spirocyclic, fused or bridged bicyclic or tricyclic C 8-14 Hydrocarbon, or partially saturated containing one or more non-aromatic unsaturated units, wherein any single ring in the bicyclic system has 3-7 members. Bicyclic carbocyclyl includes a combination of a monocyclic carbocycle and a fused ring such as phenyl. In some embodiments, the carbocyclyl group is substituted. In some embodiments, the carbocyclyl group is unsubstituted. In some embodiments, the carbocyclyl group is C 3-12 In some embodiments, the carbocyclic group is C 3-10 In some embodiments, the carbocyclic group is C 3-8 Non-limiting examples of monocyclic carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, and the like.
[0085] As used herein, the term "alkenyl" refers to a straight or branched, substituted or unsubstituted hydrocarbon chain containing one or more double bonds. In some embodiments, alkenyl is substituted. In some embodiments, alkenyl is unsubstituted. In some embodiments, alkenyl is linear, straight or unbranched. In some embodiments, alkenyl is branched.
[0086] As used herein, the term "heterocyclyl" refers to a non-aromatic (e.g., fully saturated or partially saturated and containing one or more non-aromatic unsaturated units), monocyclic or spirocyclic, fused or bridged bicyclic or tricyclic ring system, wherein one or more ring members are independently selected heteroatoms. Bicyclic heterocyclic groups include, for example, the following monocyclic combinations: a monocyclic heterocyclic group fused to a monocyclic heteroaryl; a monocyclic heterocyclic group fused to another monocyclic heterocyclic group; a monocyclic heterocyclic group fused to a phenyl group; a monocyclic heterocyclic group fused to a monocyclic carbocyclic group / cycloalkyl group; and a monocyclic heteroaryl group fused to a monocyclic carbocyclic group / cycloalkyl group. In some embodiments, the "heterocyclic group" group contains 3-14 ring members, wherein one or more ring members are heteroatoms independently selected from, for example, oxygen, sulfur, nitrogen, and phosphorus. In some embodiments, each ring in a bicyclic or tricyclic ring system contains 3-7 ring members. In some embodiments, the heterocycle has at least one unsaturated carbon-carbon bond. In some embodiments, the heterocycle has at least one unsaturated carbon-nitrogen bond. In some embodiments, the heterocycle has one heteroatom independently selected from oxygen, sulfur, nitrogen and phosphorus. In some embodiments, one heteroatom of the heterocycle is a nitrogen atom. In some embodiments, one heteroatom of the heterocycle is an oxygen atom. In some embodiments, the heterocycle has two heteroatoms each independently selected from nitrogen and oxygen atoms. In some embodiments, the heterocycle has three heteroatoms each independently selected from nitrogen and oxygen. In some embodiments, the heterocycle is substituted. In some embodiments, the heterocycle is unsubstituted. In some embodiments, the heterocyclyl is a 3-12 member heterocyclyl. In some embodiments, the heterocyclyl is a 4-10 member heterocyclyl. In some embodiments, the heterocyclyl is a 3-8 member heterocyclyl. In some embodiments, the heterocyclyl is a 5-10 member heterocyclyl. In some embodiments, the heterocyclyl is a 5-8 member heterocyclyl. In some embodiments, the heterocyclyl is a 5 or 6 member heterocyclyl. In some embodiments, the heterocyclyl is a 6 member heterocyclyl. Non-limiting examples of monocyclic heterocyclyls include piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, azetidinyl, oxetanyl, tetrahydrothiophenyl, dihydropyranyl, tetrahydropyridinyl, and the like.
[0087] The term "heteroatom" refers to one or more of oxygen, sulfur and nitrogen, including any oxidized form of nitrogen or sulfur or silicon; a quaternized form of any basic nitrogen, or; a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR +(as in N-substituted pyrrolidinyl).
[0088] As used herein, the term "unsaturated" refers to a moiety having one or more unsaturated units or degrees of unsaturation. Unsaturation means that not all available valences in the compound are satisfied by substituents, thus containing double or triple bonds.
[0089] As used herein, the term "alkoxy" refers to an alkyl group as defined above in which one carbon is substituted with an oxygen atom ("alkoxy"), provided that the oxygen atom is attached between two carbon atoms.
[0090] The term "halogen" includes F, Cl, Br and I, ie fluorine, chlorine, bromine and iodine, respectively.
[0091] As used herein, the term "cyano" or "nitrile" group refers to -C≡N.
[0092] As used herein, the term "aromatic ring" refers to a carbocyclic or heterocyclic ring containing a conjugated planar ring system having a delocalized pi electron orbital consisting of [4n+2]p orbital electrons, where n is an integer from 0 to 6. "Non-aromatic ring" refers to a carbocyclic or heterocyclic ring that does not meet the above requirements for an aromatic ring and may be fully saturated or partially saturated. Non-limiting examples of aromatic rings include aromatic rings and heteroaromatic rings, which are further defined as follows.
[0093] The term "aryl", when used alone or as part of a larger moiety such as "aralkyl", "aralkyloxy", or "aryloxyalkyl", refers to a monocyclic or spirocyclic, fused or bridged bicyclic or tricyclic ring system having a total of 5-14 ring members, wherein each ring in the system is an aromatic ring containing only carbon atoms, and wherein each ring in the bicyclic or tricyclic ring system contains 3-7 ring members. Non-limiting examples of aryl include: phenyl (C6) ring and naphthyl (C 10 ) ring. In some embodiments, the aryl group is substituted. In some embodiments, the aryl group is unsubstituted.
[0094] The term "heteroaryl" refers to a monocyclic or spirocyclic, fused or bridged bicyclic or tricyclic ring system having a total of 5-14 ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and each ring in the bicyclic or tricyclic ring system contains 3-7 ring members. Bicyclic heteroaryl includes, for example, a monocyclic combination as shown below: a monocyclic heteroaryl fused to another monocyclic heteroaryl; a monocyclic heteroaryl fused to a phenyl. In some embodiments, the heteroaryl is substituted. In some embodiments, the heteroaryl contains one or more heteroatoms, for example, selected from nitrogen, oxygen and sulfur. In some embodiments, the heteroaryl contains one heteroatom. In some embodiments, the heteroaryl contains two heteroatoms. In some embodiments, the heteroaryl is a monocyclic ring system containing five ring members. In some embodiments, the heteroaryl is a monocyclic ring system containing six ring members. In some embodiments, the heteroaryl is unsubstituted. In some embodiments, the heteroaryl is a 3-12 membered heteroaryl. In some embodiments, heteroaryl is a 3-10 membered heteroaryl. In some embodiments, heteroaryl is a 3-8 membered heteroaryl. In some embodiments, heteroaryl is a 5-10 membered heteroaryl. In some embodiments, heteroaryl is a 5-8 membered heteroaryl. In some embodiments, heteroaryl is a 5 or 6 membered heteroaryl. Non-limiting examples of monocyclic heteroaryl are: pyridyl, pyrimidinyl, thienyl, thiazolyl, isoxazolyl, etc.
[0095] "Spirocyclic system" refers to a ring system containing two or more rings, wherein each pair of rings has only one atom in common.
[0096] Non-limiting examples of suitable solvents that can be used in the present disclosure include: water, methanol (MeOH), ethanol (EtOH), dichloromethane or "methylene chloride" (CH2Cl2), toluene, acetonitrile (MeCN), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methyl acetate (MeOAc), ethyl acetate (EtOAc), heptane, isopropyl acetate (IPAc), tert-butyl acetate (t-BuOAc), isopropanol (IPA), tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-Me THF), methyl ethyl ketone (MEK), tert-butanol, diethyl ether (Et2O), methyl tert-butyl ether (MTBE), 1,4-dioxane and N-methylpyrrolidone (NMP).
[0097] Non-limiting examples of suitable bases that can be used in the present disclosure include: 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), potassium tert-butoxide (KOtBu), potassium carbonate (K2CO3), N-methylmorpholine (NMM), triethylamine (Et3N; TEA), diisopropyl-ethylamine (i-Pr2EtN; DIPEA), pyridine, potassium hydroxide (KOH), sodium hydroxide (NaOH), lithium hydroxide (LiOH) and sodium methoxide (NaOMe; NaOCH3).
[0098] Disclosed herein are pharmaceutically acceptable salts of the disclosed compounds. Salts of a compound are formed between an acid and a basic group of the compound (such as an amino functional group), or a base and an acidic group of the compound (such as a carbocyclyl functional group).
[0099] As used herein, the term "pharmaceutically acceptable" refers to a component that is suitable for use in contact with the tissues of humans and other mammals without excessive toxicity, irritation, allergic reaction, etc., and is commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. "Pharmaceutically acceptable salt" refers to any non-toxic salt that can directly or indirectly provide a compound of the present disclosure when administered to a recipient. Suitable pharmaceutically acceptable salts are, for example, disclosed in SM Berge, et al. J. Pharmaceutical Sciences, 1977, 66, pp. 1-19.
[0100] Acids commonly used to form pharmaceutically acceptable salts include: inorganic acids, such as hydrogen sulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and phosphoric acid; and organic acids, such as p-toluenesulfonic acid, salicylic acid, tartaric acid, bitartrate, ascorbic acid, maleic acid, benzenesulfonic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid, as well as related inorganic and organic acids. Such pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, octanoates, acrylates, formates, isobutyrates, decanoates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioic acid Pharmaceutically acceptable acid addition salts include, but are not limited to, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, terephthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, β-hydroxybutyrates, glycolates, maleates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, mandelates and other salts. In some embodiments, pharmaceutically acceptable acid addition salts include salts formed with mineral acids such as hydrochloric acid and hydrobromic acid, and salts formed with organic acids such as maleic acid.
[0101] Pharmaceutically acceptable salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 The present disclosure also contemplates quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Suitable non-limiting examples of alkali metal and alkaline earth metal salts include sodium, lithium, potassium, calcium and magnesium. Other non-limiting examples of pharmaceutically acceptable salts include ammonium, quaternary ammonium and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates. Other non-limiting examples of suitable pharmaceutically acceptable salts include benzoates and glucosamine salts.
[0102] The term "subject" refers to animals, including but not limited to humans.
[0103] The term "therapeutically effective amount" refers to an amount of a compound whose administration produces the desired effect (e.g., ameliorating symptoms of diseases, disorders, and conditions mediated by inhibition of kinases (e.g., HPK1); reducing the severity of diseases, disorders, and conditions mediated by inhibition of kinases (e.g., HPK1), or symptoms thereof; and / or reducing the exacerbation of diseases, disorders, and conditions mediated by inhibition of kinases (e.g., HPK1), or symptoms thereof). The exact amount of a therapeutically effective amount will depend on the purpose of the treatment, and a therapeutically effective amount can be determined by one skilled in the art using known techniques (see Lloyd (1999), The Art, Science and Technology of Pharmaceutical Compounding).
[0104] As used herein, the term "treat" and its synonyms refer to slowing or stopping the progression of a disease. As used herein, "treat" and its synonyms include, but are not limited to, the following: complete or partial relief of diseases, disorders and conditions mediated by inhibition of kinases (such as HPK1, FLT3 and Aurora kinase A), reduction in the risk of disease and the occurrence of disease-related complications. The improvement or reduction in severity of any of the above symptoms can be readily assessed according to methods and techniques known in the art or subsequently developed.
[0105] When the terms "about" and "approximately" are used in connection with the dose, amount or weight percentage of a composition or dosage form ingredient, they include the value of the specified dose, amount or weight percentage, or the range of the dose, amount or weight percentage recognized by a person of ordinary skill in the art to provide a pharmacological effect equivalent to the pharmacological effect produced by the specified dose, amount or weight percentage.
[0106] II. Compounds and Compositions
[0107] In the first embodiment, disclosed herein is a compound having a structure as shown in Formula I:
[0108]
[0109] Its tautomer, the deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the aforementioned compound, wherein:
[0110] (i)R 1 and R 2 independently selected from the group consisting of linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, linear alkenyl, branched alkenyl, cycloalkenyl, linear heteroalkenyl, branched heteroalkenyl, heteroalkenyl, linear alkynyl, branched alkynyl, cycloalkynyl, CO2R x 、C(O)NR x R y 、C(O)R x ORy 、C(O)R w N(R x R y )2、OC(O)R w NR x R y 、S(O)R y and SO2R y ;
[0111] (ii) R 3 Selected from: hydrogen, halogen groups, OR x , SR x 、NHR x 、N(R x 2. CHR x and C(R x )2;
[0112] (iii) R 4 Selected from: hydrogen, straight chain alkyl, branched chain alkyl, cycloalkyl, heterocyclic group, C(O)R y 、CO2R y 、C(O)R w OR y 、C(O)R w N(R x R y )2、OC(O)R w NR x R y , R w N(R x R y 2. R w OR x , R z R'、S(O)R y and SO2R y ;
[0113] (iv) R x and R y R is independently selected from the group consisting of hydrogen, linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl; or x and R y are linked to each other to form an optionally substituted heterocycloalkyl group;
[0114] (v)R w is absent or is selected from the group consisting of: straight chain alkyl, branched chain alkyl, cycloalkyl, carbocyclyl, heterocyclyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, straight chain heteroalkenyl, and branched chain heteroalkenyl;
[0115] (vi)R z Absent or selected from: linear alkyl, branched alkyl and cycloalkyl;
[0116] (vii) R' is selected from the group consisting of optionally substituted heteroaryl and optionally substituted heterocycloalkyl;
[0117] (viii) Ring A is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and
[0118] (ix) Ring B is selected from:
[0119] (x) wherein each R" is independently selected from: hydrogen, linear alkyl, branched alkyl and cycloalkyl; or two R" combine to form a cycloalkyl spiro ring or a heterocycloalkyl spiro ring;
[0120] wherein the straight chain alkyl, branched chain alkyl, cycloalkyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, carbocyclyl, branched chain heteroalkenyl, branched chain heteroalkenyl, straight chain alkynyl, branched chain alkynyl, cycloalkynyl, heterocyclyl, aryl and heteroaryl are optionally substituted by at least one group selected from the following groups:
[0121] Halogen groups,
[0122] Hydroxyl,
[0123] Thiols,
[0124] Amino,
[0125] Cyano,
[0126] -OC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0127] -C(O)OC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0128] -NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0129] -N(C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl)2,
[0130] -NHC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0131] -C(O)NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0132] -NH aryl,
[0133] -N(aryl)2,
[0134] -NHC(O)aryl,
[0135] -C(O)NHaryl,
[0136] -NH heteroaryl,
[0137] -N(heteroaryl)2,
[0138] -NHC(O)heteroaryl,
[0139] -C(O)NHheteroaryl,
[0140] C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0141] C2-C6 straight-chain alkenyl, branched-chain alkenyl and cycloalkenyl,
[0142] C1-C6 straight chain hydroxyalkyl, branched chain hydroxyalkyl and cyclic hydroxyalkyl,
[0143] C1-C6 straight-chain aminoalkyl, branched-chain aminoalkyl and cyclic aminoalkyl,
[0144] C1-C6 straight chain alkoxy, branched chain alkoxy and cycloalkoxy,
[0145] C1-C6 straight chain sulfanyl, branched chain sulfanyl and cyclic sulfanyl,
[0146] C1-C6 straight chain haloalkyl, branched chain haloalkyl and cyclic haloalkyl,
[0147] C1-C6 straight chain halogenated aminoalkyl, branched chain halogenated aminoalkyl and cyclic halogenated aminoalkyl,
[0148] C1-C6 straight chain halosulfanyl, branched chain halosulfanyl and cyclic halosulfanyl,
[0149] C1-C6 straight chain halogenated oxyalkyl, branched chain halogenated oxyalkyl and cyclic halogenated oxyalkyl,
[0150] benzyloxy, benzylamino and benzylthio,
[0151] 3-6 membered heterocycloalkenyl, 3-6 membered heterocyclyl, 3-6 membered spirocycloalkyl, 3-6 membered spiroheterocyclyl, and
[0152] 5-membered heteroaryl and 6-membered heteroaryl, which are optionally substituted with 0, 1 or 2 C1-C6 alkyl groups selected from the group consisting of linear alkyl, branched alkyl and cycloalkyl.
[0153] In a second embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 1 and R 2 are independently selected from: hydrogen, straight chain alkyl, branched chain alkyl and cycloalkyl, R 4 is a halogen group; all other variables not specifically defined herein are as defined in the first embodiment.
[0154] In a third embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 1 is selected from the group consisting of: C1-C6 straight chain alkyl, C1-C6 branched chain alkyl, and C1-C6 cycloalkyl; all other variables not specifically defined herein are the same as defined in the first embodiment.
[0155] In a fourth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 1 is selected from the group consisting of: methyl, ethyl, cyclopropyl, and cyclobutyl; all other variables not specifically defined herein are as defined in the third embodiment.
[0156] In a fifth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 1 is a heterocyclic group; all other variables not specifically defined herein are as defined in the first embodiment.
[0157] In a sixth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 1 is selected from the group consisting of: straight chain alkynyl, branched chain alkynyl, and cycloalkynyl; and all other variables not specifically defined herein are as defined in the first embodiment.
[0158] In a seventh embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, the straight chain alkynyl, branched chain alkynyl and cycloalkynyl groups are substituted with at least one group selected from the group consisting of C1-C6 straight chain alkyl, C1-C6 branched chain alkyl, C1-C6 cycloalkyl, C1-C6 straight chain aminoalkyl, C1-C6 branched chain aminoalkyl, C1-C6 cycloaminoalkyl, 3-6 membered heterocyclyl, 5 membered heteroaryl and 6 membered heteroaryl; all other variables not specifically defined herein are the same as defined in the sixth embodiment.
[0159] In an eighth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 2 is hydrogen; all other variables not specifically defined herein are as defined in any of the preceding embodiments.
[0160] In a ninth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 2 is selected from the group consisting of: straight chain alkyl, branched chain alkyl, and cycloalkyl; all other variables not specifically defined herein are the same as defined in any of the foregoing first to seventh embodiments.
[0161] In a tenth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 2 is selected from the group consisting of: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and cyclobutyl; all other variables not specifically defined herein are the same as defined in the ninth embodiment.
[0162] In an eleventh embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 3 is a halogen group; all other variables not specifically defined herein are as defined in any of the preceding embodiments.
[0163] In a twelfth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 3 is fluorine; all other variables not specifically defined herein are the same as defined in the eleventh embodiment.
[0164] In a thirteenth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 3 is chlorine; all other variables not specifically defined herein are the same as defined in the eleventh embodiment.
[0165] In a fourteenth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from aryl; all other variables not specifically defined herein are as defined in any of the preceding embodiments.
[0166] In a fifteenth embodiment, in a compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt of the present disclosure, Ring A is phenyl; all other variables not specifically defined herein are as defined in the fourteenth embodiment.
[0167] In a sixteenth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from aryl, wherein said aryl is substituted with a halogen group; all other variables not specifically defined herein are the same as defined in the fourteenth embodiment.
[0168] In a seventeenth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from aryl, wherein the aryl is replaced by C1-C6 straight chain alkyl, C1-C6 branched chain alkyl and C1-C6 cycloalkyl; all other variables not specifically defined herein are the same as defined in the fourteenth embodiment.
[0169] In an eighteenth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from heteroaryl; all other variables not specifically defined herein are the same as defined in any of the foregoing first to thirteenth embodiments.
[0170] In a nineteenth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from heteroaryl, wherein the heteroaryl is substituted with a halogen group; all other variables not specifically defined herein are the same as defined in the eighteenth embodiment.
[0171] In the twentieth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from heteroaryl, wherein the heteroaryl is substituted with C1-C6 straight chain alkyl, C1-C6 branched chain alkyl and C1-C6 cycloalkyl; all other variables not specifically defined herein are the same as defined in the eighteenth embodiment.
[0172] In the twenty-first embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from 6-membered heteroaryl; all other variables not specifically defined herein are the same as defined in the eighteenth embodiment.
[0173] In a twenty-second embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from a 6-membered heteroaryl group, wherein the 6-membered heteroaryl group is substituted with a halogen group; all other variables not specifically defined herein are the same as defined in the twenty-first embodiment.
[0174] In a twenty-third embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from a 6-membered heteroaryl group, wherein the 6-membered heteroaryl group is substituted with a C1-C6 straight chain alkyl group, a C1-C6 branched chain alkyl group and a C1-C6 cycloalkyl group; all other variables not specifically defined herein are the same as defined in the twenty-first embodiment.
[0175] In a twenty-fourth embodiment, in the disclosed compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts, Ring A is a pyridine ring; all other variables not specifically defined herein are as defined in the twenty-third embodiment.
[0176] In a twenty-fifth embodiment, in the disclosed compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts, Ring A is a pyrimidine ring; all other variables not specifically defined herein are as defined in the twenty-third embodiment.
[0177] In a twenty-sixth embodiment, in a compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt of the present disclosure, Ring A is selected from a 5-membered heteroaryl; all other variables not specifically defined herein are the same as defined in the eighteenth embodiment.
[0178] In a twenty-seventh embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from a 5-membered heteroaryl group, wherein the 5-membered heteroaryl group is substituted with a halogen group; all other variables not specifically defined herein are the same as defined in the twenty-sixth embodiment.
[0179] In a twenty-eighth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring A is selected from a 5-membered heteroaryl group, wherein the 5-membered heteroaryl group is substituted with a C1-C6 straight chain alkyl group, a C1-C6 branched chain alkyl group and a C1-C6 cycloalkyl group; all other variables not specifically defined herein are the same as defined in the twenty-sixth embodiment.
[0180] In a twenty-ninth embodiment, in a compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of the present disclosure, Ring A is a thiazole ring; all other variables not specifically defined herein are as defined in the twenty-eighth embodiment.
[0181] In the thirtieth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring B is All other variables not specifically defined herein have the same definitions as in any of the preceding embodiments.
[0182] In a thirty-first embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring B is All other variables not specifically defined herein are the same as defined in any of the foregoing first to thirtieth embodiments.
[0183] In a thirty-second embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring B is All other variables not specifically defined herein are the same as defined in any of the foregoing first to thirtieth embodiments.
[0184] In a thirty-third embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring B is All other variables not specifically defined herein are the same as defined in any of the foregoing first to thirtieth embodiments.
[0185] In a thirty-fourth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, Ring B is All other variables not specifically defined herein are the same as defined in any of the foregoing first to thirtieth embodiments.
[0186] In a thirty-fifth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 4 is hydrogen; all other variables not specifically defined herein are as defined in any of the preceding embodiments.
[0187] In a thirty-sixth embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 4 is selected from the group consisting of straight chain alkyl, branched chain alkyl, and cycloalkyl; all other variables not specifically defined herein are the same as defined in any of the foregoing first to thirty-fifth embodiments.
[0188] In a thirty-seventh embodiment, in the compounds, tautomers, deuterated derivatives or pharmaceutically acceptable salts of the present disclosure, R 4 is selected from the group consisting of: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and cyclobutyl; all other variables not specifically defined herein are the same as defined in the thirty-sixth embodiment.
[0189] In certain embodiments, at least one compound of the present disclosure is selected from Compounds 1-14 shown in Table 1 below, tautomers thereof, deuterated derivatives of the compounds or tautomers, or pharmaceutically acceptable salts of the foregoing compounds.
[0190] Table 1
[0191]
[0192]
[0193] Another aspect of the present disclosure provides a pharmaceutical composition comprising: at least one compound selected from the group consisting of a compound of Formula I, compounds 1-14, tautomers thereof, deuterated derivatives of said compounds or said tautomers and / or pharmaceutically acceptable salts of the foregoing compounds, or a pharmaceutical composition comprising any of the foregoing compounds; and at least one pharmaceutically acceptable carrier.
[0194] In some embodiments, the pharmaceutically acceptable carrier is selected from the group consisting of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable adjuvant. In some embodiments, the pharmaceutically acceptable carrier is selected from the group consisting of: a pharmaceutically acceptable filler, a disintegrant, a surfactant, a binder, and a lubricant.
[0195] It is also understood that the pharmaceutical compositions disclosed herein can be used in combination therapy; that is, the pharmaceutical compositions disclosed herein can further comprise additional active agents. Alternatively, the pharmaceutical composition comprises a compound selected from the group consisting of a compound of Formula I, compounds 1-14, tautomers thereof, deuterated derivatives of the compounds or tautomers thereof, or pharmaceutically acceptable salts of the foregoing compounds, or a pharmaceutical composition comprising any of the foregoing compounds can be administered as a separate composition simultaneously, before, or after a composition comprising an additional active agent.
[0196] As described above, the pharmaceutical compositions disclosed herein also include a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may be selected from: adjuvants and carriers. Pharmaceutically acceptable carriers used herein, for example, may be selected from: any and all solvents, diluents, other liquid carriers, dispersing aids, suspending aids, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders and lubricants, which are suitable for the specific dosage form required. Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. DB Troy; Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JCBoylan, 1988 to 1999, Marcel Dekker, New York disclose various carriers used in the preparation of pharmaceutical compositions, and known preparation techniques thereof. Unless any conventional carrier is incompatible with the compounds disclosed herein, such as producing any adverse biological effects or having a harmful interaction with any other component of the pharmaceutical composition, its use should be within the scope of the present disclosure. Non-limiting examples of suitable pharmaceutically acceptable carriers include: ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates, glycine, sorbic acid and potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts and electrolytes (such as sulphate protein amine, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, lanolin, sugars (such as lactose, glucose and sucrose), starches (such as corn starch and potato starch), cellulose and its derivatives (such as carboxylic acid). sodium methylcellulose, ethylcellulose and cellulose acetate), tragacanth powder, malt, gelatin, talc, excipients (such as cocoa butter and suppository wax), oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil), glycols (such as propylene glycol and polyethylene glycol), esters (such as ethyl oleate and ethyl laurate), agar, buffers (such as magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, phosphate buffer solution, non-toxic compatible lubricants (such as sodium lauryl sulfate and magnesium stearate), coloring agents, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives and antioxidants.
[0197] III. Methods of treatment and use
[0198] In another aspect of the present disclosure, the compounds, tautomers, deuterated derivatives, or pharmaceutically acceptable salts disclosed herein, including compounds of formula I, compounds 1-14, tautomers thereof, deuterated derivatives of the compounds or tautomers, or pharmaceutically acceptable salts of the foregoing compounds, or pharmaceutical compositions thereof, are used to treat diseases, disorders, or conditions mediated by protein kinase inhibition. In another aspect, disclosed herein are uses of compounds, tautomers, deuterated derivatives, and / or pharmaceutically acceptable salts thereof, including compounds of formula I, compounds 1-14, tautomers thereof, deuterated derivatives of the compounds or tautomers, and / or pharmaceutically acceptable salts of the foregoing compounds, or pharmaceutical compositions thereof, for the preparation of medicaments for treating diseases, disorders, or conditions mediated by protein kinase inhibition. In another aspect, disclosed herein is a method of treating a disease, disorder or condition mediated by protein kinase inhibition in a subject, comprising administering a therapeutically effective amount of a compound, tautomer, deuterated derivative and / or pharmaceutically acceptable salt of the present disclosure, including a compound of Formula I, Compounds 1-14, tautomers thereof, deuterated derivatives of the compound or tautomers and / or pharmaceutically acceptable salts of the foregoing compounds, or a pharmaceutical composition thereof.
[0199] In some embodiments, the protein kinase is selected from the group consisting of: hematopoietic progenitor kinase 1 (HPK1), Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinase A.
[0200] In some embodiments, the disease, disorder or condition is selected from a protein kinase-related disease. In some embodiments, the disease, disorder or condition is selected from a FLT3-related disease. In some embodiments, the disease, disorder or condition is selected from an Aurora kinase A-related disease.
[0201] In some embodiments, the disease, disorder or condition is cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the solid tumor is selected from: brain cancer, breast cancer, respiratory tract cancer and / or lung cancer, reproductive organ cancer, bone cancer, digestive tract cancer, urethral cancer, eye cancer, liver cancer, skin cancer, head and neck cancer, anal cancer, nervous system cancer, thyroid cancer and parathyroid cancer. In some embodiments, the cancer is a blood cancer. In some embodiments, the blood cancer is selected from: acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), T-cell lymphoma (TCL), Burkitt's lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and myelodysplastic syndrome (MDS).
[0202] In some embodiments, the cancer is selected from: oral (e.g., buccal cavity, lip, tongue, mouth, pharynx) epidermoid carcinoma; cardiac cancer, such as sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyosarcoma, fibroma, lipoma and teratoma; lung cancer, such as bronchial cancer (squamous cell or epidermal cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatosis, hamartoma, mesothelioma; gastrointestinal cancer, such as esophageal (squamous cell carcinoma, laryngeal cancer, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreatic (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor Cancers of the genitourinary tract, including kidney (adenocarcinoma, Wilms' tumor (Nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma), liver cancer, such as hepatocellular carcinoma (hepatoma), and testicular cancer. cell carcinoma), bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary cancer; bone cancer, such as osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor; cancers of the nervous system, including skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningosarcomas, gliomatosis), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors ( Gynecological cancers, including uterus (endometrial cancer), cervix (cervical cancer, preneoplastic cervical dysplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), ovarian granulosa cell-follicular cell tumor, ovarian supporting cell-stromal cell tumor, asexual cell carcinoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma), breast cancer;Blood cancers, such as blood cancers (myeloid leukemia (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma), hair cell; lymphatic system diseases; skin cancers, including malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, keratoacanthoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; thyroid cancers, such as papillary thyroid cancer, follicular thyroid cancer; medullary thyroid cancer, anaplastic thyroid cancer, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and adrenal gland cancers, such as neuroblastoma. ;
[0203] In another aspect of the present disclosure, the compounds, tautomers, deuterated derivatives and / or pharmaceutically acceptable salts disclosed herein, including compounds of formula I, compounds 1-14, their tautomers, deuterated derivatives of the compounds or the tautomers and / or pharmaceutically acceptable salts of the aforementioned compounds, or pharmaceutical compositions thereof, are used to reduce protein kinase activity. In another aspect, disclosed herein are uses of compounds, tautomers, deuterated derivatives and / or pharmaceutically acceptable salts of the present disclosure, including compounds of formula I, compounds 1-14, their tautomers, deuterated derivatives of the compounds or the tautomers and / or pharmaceutically acceptable salts of the aforementioned compounds, or pharmaceutical compositions thereof, for preparing drugs that reduce protein kinase activity. In another aspect, disclosed herein is a method for reducing protein kinase activity, comprising administering to a subject a therapeutically effective amount of a compound, tautomer, deuterated derivative, and / or pharmaceutically acceptable salt disclosed herein, including a compound of Formula I, Compounds 1-14, tautomers thereof, deuterated derivatives of the compound or the tautomer, and / or pharmaceutically acceptable salts of the foregoing compounds, or pharmaceutical compositions thereof. In another aspect, disclosed herein is a method for reducing protein kinase activity, comprising contacting the protein kinase with a compound, tautomer, deuterated derivative, and / or pharmaceutically acceptable salt disclosed herein, including a compound of Formula I, Compounds 1-14, tautomers thereof, deuterated derivatives of the compound or the tautomer, and / or pharmaceutically acceptable salts of the foregoing compounds, or pharmaceutical compositions thereof.
[0204] The compound of Formula I, compounds 1-14, tautomers thereof, deuterated derivatives of said compounds or said tautomers and / or pharmaceutically acceptable salts of the foregoing compounds, or pharmaceutical compositions thereof, can be administered once, twice or three times daily, for example, for the treatment of diseases, disorders or conditions mediated by protein kinase inhibition.
[0205] In some embodiments, 2-1500 mg of a compound of formula I, compound 1-14, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing compound or a pharmaceutical composition thereof is administered once a day, twice a day, or three times a day. For example, in some embodiments, at least one of a compound of formula I, compound 1-14, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing compound or a pharmaceutical composition thereof is administered once a day, twice a day, or three times a day: 5-1000 mg, 10-500 mg, 20-300 mg, 20-200 mg, 30-150 mg, 50-150 mg, 60-125 mg, or 70-120 mg, 80-115 mg, 90-110 mg, 95-110 mg, or 100-105 mg.
[0206] Formula I compound, compound 1-14, its tautomer, the deuterated derivative of the compound or the tautomer and / or the pharmaceutically acceptable salt of the aforementioned compound or its pharmaceutical composition can be, for example, administered orally, parenterally, sublingually, topically, rectally, nasally, buccally, vaginally, transdermally, patch, pump or administered by an implantable reservoir, and the pharmaceutical composition will be formulated accordingly. Parenteral administration includes, for example, intravenous, intraperitoneal, subcutaneous, intramuscular, transdermal, nasal, intrapulmonary, intrathecal, rectal and topical administration. Parenteral administration, for example, can be continuously infused over a selected time. Other forms of administration are contemplated in the present disclosure as described in international patent applications WO2013 / 075083, WO2013 / 075084, WO2013 / 078320, WO2013 / 120104, WO2014 / 124418, WO2014 / 151142 and WO2015 / 023915.
[0207] The useful dosage or therapeutically effective amount of the compounds disclosed herein or their pharmaceutically acceptable salts can be determined by comparing their in vitro activity and in vivo activity in animal models. Methods for extrapolating effective doses in mice and other animals to humans are known in the art, for example, see U.S. Pat. No. 4,938,949.
[0208] One of ordinary skill in the art will recognize that when an amount of a compound is disclosed, the relevant amount of a pharmaceutically acceptable salt form of the compound is an amount equivalent to the concentration of the free base of the compound. The amounts of the compounds, tautomers, pharmaceutically acceptable salts, and deuterated derivatives disclosed herein are based on the free base form of the reference compound. For example, "1000 mg of at least one compound selected from the group consisting of a compound of Formula I and a pharmaceutically acceptable salt thereof" includes 1000 mg of a compound of Formula I and a pharmaceutically acceptable salt of a compound of Formula I equivalent to 1000 mg of a compound of Formula I.
[0209] In another aspect of the present disclosure, the compounds and compositions disclosed herein can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (drug combinations) or methods, such as antiproliferative agents, anticancer agents, immunomodulators or anti-inflammatory agents and / or non-drug therapies, etc. For example, a synergistic effect can be produced together with antiproliferative, anticancer, immunomodulatory or anti-inflammatory substances. When the compounds disclosed herein are used in combination with other therapies, the dosage of the compounds used in combination will of course vary depending on the type of combined drug used, the specific drug used, the condition being treated, etc. Combination therapy includes further combining the compounds with one or more other biologically active ingredients (such as a second kinase inhibitor, a second different anti-tumor drug) and non-drug therapies (such as surgery or radiotherapy). For example, the compounds disclosed herein can be used in combination with other pharmaceutically active compounds (preferably compounds that can enhance the effects of the compounds disclosed herein). The compounds disclosed herein can be administered simultaneously (as a single preparation or a separate preparation) or sequentially with other drug therapies or treatment methods. In general, combination therapy refers to the administration of two or more drugs in one treatment cycle or course of treatment. In another aspect of the present disclosure, the compounds may be administered in combination with one or more separate pharmaceutical agents, such as chemotherapeutic agents, immunotherapeutic agents, or adjuvant therapy agents.In one embodiment, the separate agent is selected from: anti-PD1 antibodies (such as pembrolizumab), HDAC inhibitors (such as panobinostat, romidepsin, vorinostat or citarinostat), BCL-2 inhibitors (such as venetoclax), BTK inhibitors (such as ibrutinib or acalabrutinib), mTOR inhibitors (such as everolimus), PI3K inhibitors (such as adranib), PKCβ inhibitors (such as enzastaurin), SYK inhibitors ( such as fotantinib), JAK2 inhibitors (such as fudatinib, paclitinib, ruxolitinib, baricitinib, gandutinib, lestaurtinib, or molotinib), Aurora kinase inhibitors (such as alecetin), EZF12 inhibitors (such as tazemetostat, GSK126, CPI-1205, 3-deazaadenine A, EPZ005687, Ell, UNC1999, or sinefungin), BET inhibitors (such as bilaricev), hypomethylating agents (such as 5-azacytidine or dezempic tadalafil), DOT1L inhibitors (such as pinostat), FIAT inhibitors (such as C646), WDR5 inhibitors (such as OICR-9429), DNMT1 inhibitors (such as GSK3484862), LSD-1 inhibitors (such as compound C or celidestat), G9A inhibitors (such as UNC0631), PRMT5 inhibitors (such as GSK3326595), BRD inhibitors (such as LP99), SUV420FU / F12 inhibitors (such as A-196), CARM1 inhibitors (such as EZM2302), PLK1 inhibitors (such as BI2536), NEK2 inhibitors (such as JF1295), MEK inhibitors (such as trametinib, bemetinib, cobimetinib, selumetinib), PF1F19 inhibitors, PIM inhibitors (such as LGF1-447), IGF-IR inhibitors (such as linsitinib), XP01 inhibitors (such as selinexor), BIRC5 inhibitors (such as YM1 55), PARP inhibitors (such as olaparib), EGFR inhibitors (such as osimertinib), HER2 / NEU inhibitors (such as tucatinib), SRC inhibitors (such as dasatinib), AKT inhibitors (such as patasertib), KRAS (G12C) inhibitors (such as sotolacib), KRAS (G12D) inhibitors (such as MRTX1133), platinum or chemotherapy agents (such as bendamustine, bleomycin, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, cisplatin, taxanes or dexamethasone).
[0210] Non-limiting example embodiments
[0211] 1. Compounds of formula I:
[0212]
[0213] Its tautomer, the deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the aforementioned compound, wherein:
[0214] (i)R 1 and R 2 independently selected from the group consisting of linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, linear alkenyl, branched alkenyl, cycloalkenyl, linear heteroalkenyl, branched heteroalkenyl, heteroalkenyl, linear alkynyl, branched alkynyl, cycloalkynyl, CO2R x 、C(O)NR x R y 、C(O)R x OR y 、C(O)R w N(R x R y )2、OC(O)R w NR x R y 、S(O)R y and SO2R y ;
[0215] (ii) R 3 Selected from: hydrogen, halogen groups, OR x , SR x 、NHR x 、N(R x 2. CHR x and C(R x )2;
[0216] (iii) R 4 Selected from: hydrogen, straight chain alkyl, branched chain alkyl, cycloalkyl, heterocyclic group, C(O)R y 、CO2R y 、C(O)R w OR y 、C(O)R w N(R x R y )2、OC(O)R w NR x R y , R w N(R x R y 2. R w OR x , R z R'、S(O)R y and SO2R y ;
[0217] (iv) R x and R yR is independently selected from the group consisting of hydrogen, linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl; or x and R y are linked to each other to form an optionally substituted heterocycloalkyl group;
[0218] (v)R w Absent or selected from the group consisting of: straight chain alkyl, branched chain alkyl, cycloalkyl, carbocyclyl, heterocyclyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, straight chain heteroalkenyl and branched chain heteroalkenyl;
[0219] (vi)R z Absent or selected from: linear alkyl, branched alkyl and cycloalkyl;
[0220] (vii) R' is selected from the group consisting of optionally substituted heteroaryl and optionally substituted heterocycloalkyl;
[0221] (viii) Ring A is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and
[0222] (ix) Ring B is selected from:
[0223] (x) wherein each R" is independently selected from: hydrogen, linear alkyl, branched alkyl and cycloalkyl; or two R" combine to form a cycloalkyl spiro ring or a heterocycloalkyl spiro ring;
[0224] wherein the straight chain alkyl, branched chain alkyl, cycloalkyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, carbocyclyl, branched chain heteroalkenyl, branched chain heteroalkenyl, straight chain alkynyl, branched chain alkynyl, cycloalkynyl, heterocyclyl, aryl and heteroaryl are optionally substituted by at least one group selected from the following groups:
[0225] Halogen groups,
[0226] Hydroxyl,
[0227] Thiols,
[0228] Amino,
[0229] Cyano,
[0230] -OC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0231] -C(O)OC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0232] -NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0233] -N(C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl)2,
[0234] -NHC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0235] -C(O)NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0236] -NH aryl,
[0237] -N(aryl)2,
[0238] -NHC(O)aryl,
[0239] -C(O)NHaryl,
[0240] -NH heteroaryl,
[0241] -N(heteroaryl)2,
[0242] -NHC(O)heteroaryl,
[0243] -C(O)NHheteroaryl,
[0244] C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl,
[0245] C2-C6 straight-chain alkenyl, branched-chain alkenyl and cycloalkenyl,
[0246] C1-C6 straight chain hydroxyalkyl, branched chain hydroxyalkyl and cyclic hydroxyalkyl,
[0247] C1-C6 straight-chain aminoalkyl, branched-chain aminoalkyl and cyclic aminoalkyl,
[0248] C1-C6 straight chain alkoxy, branched chain alkoxy and cycloalkoxy,
[0249] C1-C6 straight chain sulfanyl, branched chain sulfanyl and cyclic sulfanyl,
[0250] C1-C6 straight chain haloalkyl, branched chain haloalkyl and cyclic haloalkyl,
[0251] C1-C6 straight chain halogenated aminoalkyl, branched chain halogenated aminoalkyl and cyclic halogenated aminoalkyl,
[0252] C1-C6 straight chain halosulfanyl, branched chain halosulfanyl and cyclic halosulfanyl,
[0253] C1-C6 straight chain halogenated oxyalkyl, branched chain halogenated oxyalkyl and cyclic halogenated oxyalkyl,
[0254] benzyloxy, benzylamino and benzylthio,
[0255] 3-6 membered heterocycloalkenyl, 3-6 membered heterocyclyl, 3-6 membered spirocycloalkyl, 3-6 membered spiroheterocyclyl, and
[0256] 5-membered heteroaryl and 6-membered heteroaryl, which are optionally substituted with 0, 1 or 2 C1-C6 alkyl groups selected from the group consisting of linear alkyl, branched alkyl and cycloalkyl.
[0257] 2. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in Embodiment 1, wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, linear alkyl, branched alkyl and cycloalkyl, and R4 is a halogen group.
[0258] 3. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in Embodiment 1 or 2, wherein R 1 Selected from: C1-C6 straight chain alkyl, C1-C6 branched chain alkyl and C1-C6 cycloalkyl.
[0259] 4. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in Embodiment 3, wherein R 1 Selected from: methyl, ethyl, cyclopropyl and cyclobutyl.
[0260] 5. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in Embodiment 1, wherein R 1 It is a heterocyclic group.
[0261] 6. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in Embodiment 1, wherein R 1 Selected from: straight chain alkynyl, branched chain alkynyl and cycloalkynyl.
[0262] 7. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in Embodiment 6, wherein the straight-chain alkynyl, branched-chain alkynyl and cycloalkynyl are substituted with at least one group selected from the group consisting of C1-C6 straight-chain alkyl, C1-C6 branched-chain alkyl and C1-C6 cycloalkyl, C1-C6 straight-chain aminoalkyl, C1-C6 branched-chain aminoalkyl, C1-C6 cycloaminoalkyl, 3-6 membered heterocyclyl, 5 membered heteroaryl and 6 membered heteroaryl.
[0263] 8. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in any one of embodiments 1-7, wherein R 2 It's hydrogen.
[0264] 9. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in any one of embodiments 1-7, wherein R 2 Selected from: straight chain alkyl, branched chain alkyl and cycloalkyl.
[0265] 10. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 9, wherein R2 Selected from: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and cyclobutyl.
[0266] 11. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of embodiments 1-3, wherein R 3 is a halogen group.
[0267] 12. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 11, wherein R 3 It's fluorine.
[0268] 13. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 11, wherein R 3 It's chlorine.
[0269] 14. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of embodiments 1-13, wherein ring A is selected from aryl.
[0270] 15. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 14, wherein Ring A is phenyl.
[0271] 16. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 14, wherein ring A is selected from an aryl group, and the aryl group is substituted with a halogen group.
[0272] 17. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in embodiment 14, wherein ring A is selected from aryl, and the aryl is replaced by C1-C6 straight chain alkyl, branched alkyl and cycloalkyl; all other variables not specifically defined herein are the same as defined in the fourteenth embodiment.
[0273] 18. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in any one of embodiments 1-13, wherein ring A is selected from heteroaryl.
[0274] 19. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 18, wherein ring A is selected from heteroaryl, and the heteroaryl is substituted with a halogen group.
[0275] 20. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in embodiment 18, wherein ring A is selected from heteroaryl, wherein the heteroaryl is substituted with C1-C6 straight chain alkyl, C1-C6 branched alkyl and C1-C6 cycloalkyl.
[0276] 21. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 18, wherein ring A is selected from a 6-membered heteroaryl group.
[0277] 22. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 21, wherein ring A is selected from a 6-membered heteroaryl group, and the 6-membered heteroaryl group is substituted with a halogen group.
[0278] 23. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in embodiment 21, wherein ring A is selected from a 6-membered heteroaryl group, and the 6-membered heteroaryl group is substituted with a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group and a C1-C6 cycloalkyl group.
[0279] 24. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 23, wherein Ring A is a pyridine ring.
[0280] 25. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 23, wherein Ring A is a pyrimidine ring.
[0281] 26. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 18, wherein ring A is selected from a 5-membered heteroaryl group.
[0282] 27. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of embodiment 26, wherein ring A is selected from a 5-membered heteroaryl group, and the 5-membered heteroaryl group is substituted with a halogen group.
[0283] 28. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in embodiment 26, wherein ring A is selected from a 5-membered heteroaryl group, and the 5-membered heteroaryl group is substituted with a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group and a C1-C6 cycloalkyl group.
[0284] 29. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 28, wherein Ring A is a thiazole ring.
[0285] 30. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 1, wherein Ring B is
[0286] 31. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 1, wherein Ring B is
[0287] 32. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 1, wherein Ring B is
[0288] 33. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 1, wherein Ring B is
[0289] 34. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of Embodiment 1, wherein Ring B is
[0290] 35. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in any one of embodiments 1-34, wherein R 4 It's hydrogen.
[0291] 36. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in any one of embodiments 1-34, wherein R 4 Selected from: straight chain alkyl, branched chain alkyl and cycloalkyl.
[0292] 37. A compound, tautomer, deuterated derivative or pharmaceutically acceptable salt as described in any one of embodiments 1-34, wherein R 4 Selected from: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and cyclobutyl.
[0293] 38. A compound selected from the group consisting of:
[0294]
[0295]
[0296] Its tautomer, the deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the aforementioned compound.
[0297] 39. A pharmaceutical composition comprising a compound, tautomer, deuterated derivative or pharmaceutically acceptable salt according to any one of embodiments 1-38, and at least one pharmaceutically acceptable carrier.
[0298] 40. A method of treating or ameliorating a disease, disorder or condition mediated by protein kinase inhibition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of embodiments 1-38 or a pharmaceutical composition of embodiment 39.
[0299] 41. A method as described in embodiment 40, wherein the protein kinase is selected from: hematopoietic progenitor kinase 1 (HPK1), Fms-like tyrosine kinase 3 receptor (FLT3) and Aurora kinase A.
[0300] 42. A method of reducing protein kinase activity in a disease, disorder or condition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, tautomer, deuterated derivative and / or pharmaceutically acceptable salt of any one of Embodiments 1-38 or a pharmaceutical composition of Embodiment 39.
[0301] 43. The method of embodiment 40 or 42, wherein the disease, disorder or condition is selected from a protein kinase-related disease.
[0302] 44. The method of embodiment 43, wherein the protein kinase-related disease is cancer.
[0303] 45. The method of embodiment 44, wherein the cancer is a solid tumor.
[0304] 46. A method as described in embodiment 45, wherein the solid tumor is selected from brain cancer, breast cancer, respiratory tract cancer and / or lung cancer, reproductive organ cancer, bone cancer, digestive tract cancer, urethral cancer, eye cancer, liver cancer, skin cancer, head and neck cancer, anal cancer, nervous system cancer, thyroid cancer and parathyroid cancer.
[0305] 47. The method of embodiment 44, wherein the cancer is a blood cancer.
[0306] 48. The method of embodiment 47, wherein the blood cancer is selected from the group consisting of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and myelodysplastic syndrome (MDS).
[0307] 49. A method as described in embodiment 44, wherein the cancer is selected from oral (e.g., buccal cavity, lip, tongue, mouth, pharynx) epidermoid carcinoma; cardiac cancer, such as sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyosarcoma, fibroma, lipoma and teratoma; lung cancer, such as bronchial cancer (squamous cell or epidermal cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatosis, hamartoma, mesothelioma; gastrointestinal cancer, such as esophageal (squamous cell carcinoma, laryngeal cancer, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreatic (ductal adenocarcinoma, insulinoma, glucagonoma, gastric cancer) Cancers of the small intestine or large intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine or large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyosarcoma), colon, colorectum, colorectum, rectum; genitourinary tract cancers, including kidney (adenocarcinoma, Wilms' tumor (Nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma); liver cancers, such as hepatocellular carcinoma cell tumors (hepatocellular carcinoma), bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hepatic hemangioma, biliary cancer; bone cancers, such as osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor; cancers of the nervous system, including skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningosarcomas, gliomatosis), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealoma, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal neurofibroma, meningioma, glioma, sarcoma); gynecological cancers, including uterus (endometrial cancer), cervix (cervical cancer, preneoplastic cervical dysplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), ovarian granulosa cell-follicular cell tumor, ovarian supporting cell-stromal cell tumor, asexual cell carcinoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma), breast cancer;Blood cancers, such as blood cancers (myeloid leukemia (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma), hair cell; lymphatic system diseases; skin cancers, including malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, keratoacanthoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; thyroid cancers, such as papillary thyroid cancer, follicular thyroid cancer; medullary thyroid cancer, anaplastic thyroid cancer, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and adrenal gland cancers, such as neuroblastoma. ;
[0308] 50. The method of embodiment 40 or 42, further comprising administering an existing standard therapy or an FDA-approved therapy to the subject.
[0309] 51. The method of embodiment 40 or 42, further comprising administering one or more separate agents to the subject.
[0310] 52. The method of embodiment 51, wherein the separate agent is selected from: a chemotherapeutic agent, an immunotherapeutic agent, and an adjuvant therapeutic agent. Example
[0311] Example 1: Synthesis of compounds
[0312] In order to fully understand the present disclosure, the following examples are disclosed. It should be understood that these examples are for illustrative purposes only and should not be interpreted as limiting the present disclosure in any way.
[0313] All specific and generic compounds as well as intermediates disclosed for making these compounds are considered to be part of this disclosure.
[0314] The compounds of the present disclosure can be prepared according to standard chemical practices or methods disclosed herein. Throughout the following synthetic schemes, as well as in the description of the preparation of compounds of Formula I, compounds 1-14, pharmaceutically acceptable salts of any of the foregoing compounds, solutions of any of the foregoing compounds, and deuterated derivatives of any of the foregoing compounds, the following abbreviations are used:
[0315] abbreviation
[0316] = Angstrom
[0317] Ac = acetyl
[0318] Ac2O=Acetic anhydride
[0319] Boc2O=di-tert-butyl dicarbonate
[0320] DCM = dichloromethane
[0321] DIEA = N,N-diisopropylethylamine or N-ethyl-N-isopropyl-2-propylamine
[0322] DMAP = dimethylaminopyridine
[0323] DMA = dimethylacetamide
[0324] DME = dimethoxyethane
[0325] DMF = dimethylformamide
[0326] DMSO = dimethyl sulfoxide
[0327] EtOAc / EA=Ethyl acetate
[0328] EtOH = ethanol
[0329] HOAc=acetic acid
[0330] KOAc = Potassium acetate
[0331] LiHMDS = Lithium Bis(trimethylsilyl)amide
[0332] MeMgBr = methylmagnesium bromide
[0333] MeOH = methanol
[0334] NaOAc = Sodium acetate
[0335] NBS = N-bromosuccinimide
[0336] Pd(dppf)2Cl2=[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
[0337] PTSA = p-toluenesulfonic acid monohydrate
[0338] rt = room temperature (ambient temperature)
[0339] T3P = 2,4,6-tripropyl-1,3,5,2,4,6-trioxytriphosphine-2,4,6-trioxide
[0340] TEA = triethylamine
[0341] TFA = trifluoroacetic acid
[0342] THF = Tetrahydrofuran
[0343] TsCl = p-Toluenesulfonyl chloride
[0344] UV = Ultraviolet
[0345] X-Phos=2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
[0346] Intermediate Preparation:
[0347] Intermediate A1: 5-bromo-4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridine
[0348]
[0349] Step 1. Preparation of 1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one:
[0350] To a solution of 5-bromo-1H-pyrrolo[2,3-b]pyridine (50 g, 0.25 mol) in DCM (550 mL) was added AlCl3 (101.27 g, 0.76 mol) and acetyl chloride (21.92 g, 0.28 mol) at 0°C under N2. The reaction mixture was stirred at room temperature for 7 h under N2. MeOH (300 mL) was added to the reaction mixture and the solvent was removed under reduced pressure. The reaction solution was adjusted to pH 6-7 with 3N NaOH aqueous solution and then extracted with EA (500 mLx3). The combined organic layers were washed with brine (300 mLx3) and then dried over anhydrous Na2SO4. After filtration, the solution was concentrated in vacuo and the crude product was purified by Combiflash (PE / EtOAc=2:1) to give a yellow solid product 1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one (43.24 g, 71%). Mass (m / z): 241.0 [M+H] + .
[0351] Step 2. Preparation of 5-bromo-3-ethyl-1H-pyrrolo[2,3-b]pyridine:
[0352] LiAlH4 (4.39 g, 0.1 mol) and 1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one (10 g, 0.04 mol) were added to a solution of AlCl3 (27.8 g, 0.20 mol) in DME (200 mL) at 0°C. The reaction mixture was stirred at room temperature for 3 h under N2. After the reaction was completed, H2O (500 mL) was added to the reaction mixture, which was then extracted with EA (200 mL x 3). The combined organic layers were washed with brine (100 mL x 2) and then dried over anhydrous Na2SO4. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give the product 5-bromo-3-ethyl-1H-pyrrolo[2,3-b]pyridine (11.5 g, 74%) as a yellow solid compound. Mass (m / z): 225.0 [M+H] + .
[0353] Step 3. Preparation of 5-bromo-3-ethyl-1H-pyrrolo[2,3-b]pyridine 7-oxide:
[0354] To a solution of A1-3 (25 g, 0.11 mol) in EA (100 mL) was added 3-chloroperoxybenzoic acid (26.84 g, 0.155 mol). The reaction mixture was stirred at room temperature for 3 h. The solution was washed with saturated Na2CO3 (20 mL) and brine (20 mL), and then dried over anhydrous Na2SO4. The reaction mixture was filtered and the filtrate was concentrated to dryness to give the desired product as a white solid (17.4 g, yield: 64.6%). Mass (m / z): 240.7 [M+H] + .
[0355] Step 4. Preparation of 5-bromo-4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridine:
[0356] Phosphorus trichloride (55.05 g, 35.9 mmol) was added to a solution of A1-4 (17.3 g, 71.8 mmol) in NMP (15 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 16 h. The mixture was quenched with water (50 mL), extracted with EA (30 mL x 3), washed with saturated brine, filtered, concentrated, and the residue was purified by flash column (PE / EA = 5: 1) to obtain the desired white solid product (4.1 g, yield: 22%). Mass (m / z): 258.7 [M+H] + .
[0357] Intermediate A2: 5-bromo-4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine
[0358]
[0359] Step 1. Preparation of 5-bromo-4-chloropyridin-2-amine:
[0360] NBS (458 g, 2.57 mol, 1.1 eq) was added to a solution of 4-chloropyridin-2-amine (300 g, 2.34 mol, 1.0 eq) in acetonitrile (3000 mL) in portions. The reaction mixture was stirred at room temperature for 6 h. The reactants were then poured into water and filtered. The filter cake was washed with polyethylene (PE) and dried to give a yellow solid compound 5-bromo-4-chloropyridin-2-amine (407 g, yield 83.9%). Mass (m / z): 207 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ8.10(s,1H),6.67(s,1H),6.45(s,2H).
[0361] Step 2. Preparation of 5-bromo-4-chloro-3-iodopyridin-2-amine:
[0362] NIS (666 g, 2.96 mol, 1.5 eq) was added to a solution of compound 5-bromo-4-chloropyridin-2-amine (407 g, 1.97 mol, 1.0 eq) in AcOH (2000 mL) in several portions. The reaction mixture was stirred at 80 ° C for 6 h. The reactant was cooled to room temperature, poured into ice water (5000 mL), adjusted to pH>7 with K2CO3, extracted with EA (5000 mLx3), and washed with Na2SO3 solution (5000 mL) and brine (5000 mL). The organic phase was concentrated in vacuo to obtain a yellow solid compound 5-bromo-4-chloro-3-iodopyridin-2-amine (500 g, yield 76.3%). Mass (m / z): 332.7 [M+H] + . 1 HNMR (400MHz, DMSO-d6) δ8.10 (s, 1H), 6.62 (s, 2H).
[0363] Step 3. Preparation of 5-bromo-4-chloro-3-cyclopropyl-2-(trimethylsilyl)-1H-pyrrolo[2,3-b]pyridine:
[0364] Pd(PPh3)2Cl2 (21.1 g, 0.03 mol, 0.1 eq) was added to a solution of 5-bromo-4-chloro-3-iodopyridin-2-amine (100 g, 0.300 mol, 1.0 eq) and DABCO (101 g, 0.900 mol, 3.0 eq) in DMF (2000 mL) under N2. Compound (cyclopropylethynyl)trimethylsilane (166 g, 1.20 mol, 4.0 eq) was then added. The reactants were degassed 3 times under N2. The reaction mixture was stirred at 120°C for 10 h. The reactants were filtered, quenched with water (2000 mL), extracted with EA (2000 mLx3), washed with brine (2000 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by chromatography on silica gel with THF / PE (1:15) to obtain a yellow solid compound 5-bromo-4-chloro-3-cyclopropyl-2-(trimethylsilyl)-1H-pyrrolo[2,3-b]pyridine (27 g, yield 26.2%). Mass (m / z): 344.9 [M+H] + .
[0365] Step 4. Preparation of 5-bromo-4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine:
[0366] To a mixture of compound 5-bromo-4-chloro-3-cyclopropyl-2-(trimethylsilyl)-1H-pyrrolo[2,3-b]pyridine (27g, 79.0mmol, 1.0eq) and THF (237mL), TBAF in THF (1.0M, 237mL, 3.0eq) and H2O (4.27g, 237mmol, 3.0eq) solution was added. The reaction mixture was stirred at room temperature for 1h. The reactant was quenched with water (1000mL), extracted with EA (1000mLx3), washed with brine (1000mL), dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by THF / PE (1:4) chromatography on silica gel to obtain the product compound 5-bromo-4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine (15g, yield 70.4%) as a light yellow solid. Mass (m / z): 272.9 [M+H] + . 1 HNMR (400MHz, DMSO-d6) δ11.92(s,1H),8.36(s,1H),7.33–7.34(d,J=4.0Hz,1H),2.11–2.16(m,1H),0.84–0.86(m,2H),0.62–0.64(m,2H).
[0367] General Synthesis Procedure I:
[0368]
[0369] Step 1. Preparation of G-2:
[0370] To a mixture of G-1 (1.24 mmol) and dioxane (5 mL) were added KOAc (3.73 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (379 mg, 1.49 mmol) and Pd(dppf)Cl2 (54 mg, 0.074 mmol). The reaction mixture was degassed with N2 three times and stirred at 110°C under N2 for 2 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EA = 0-40%) to give the product G-2.
[0371] Step 2. Preparation of G-3:
[0372] To a mixture of G-2 (0.764 mmol) and dioxane / H2O (10:1, 5.00 mL) was added K2CO3 (317 mg, 2.29 mmol), intermediate A1 or intermediate A2 (0.764 mmol), and Pd(dppf)Cl2 (55 mg, 0.0763 mmol). The reactants were degassed with N2 three times and stirred at 90°C for 16 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was diluted with water (20 mL), then extracted with EA (20 mLx3), washed with brine (30 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by preparative HPLC [Gemini-C18, 150x21.2 mm, 5 um; ACN--H2O (0.1% FA), 40-60] to give the product.
[0373] Compound 1: 4-(3-(4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
[0374]
[0375] Step 1. 4-(3-bromophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one: A mixture of 3-bromoaniline (6.01 g, 34.9 mmol), methyl carbazate (3 g, 33.3 mmol), triethyl orthoformate (4.94 g, 33.3 mmol) and TsOH (0.13 g, 0.6 mmol) in MeOH (80 mL) was stirred at 65 °C under N2 for 3 h. After cooling to room temperature, NaOMe (5.4 g, 99.9 mmol) was added and the mixture was stirred at room temperature for 18 h. After vacuum concentration, EA (80 mL) and H2O (80 mL) were added to the residue, which was then acidified to pH 5-6 with 1N aq hydrochloric acid. The aqueous phase was extracted with EA (80 mL x 3). The combined organic layers were washed with H2O (100 mL) and then washed twice with 1N aq NaOH solution. The combined NaOH extracts were acidified with concentrated hydrochloric acid, and the resulting solid was collected by filtration, rinsed with H2O and dried to give the desired product as a white solid (2 g, 25%). Mass (m / z): 239.9 [M+H] + .
[0376] Step 2. According to the general synthetic procedure I, a white solid compound 4-(3-(4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (6 mg, 4%) was obtained from 4-(3-bromophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one and intermediate A1. Mass (m / z): 453.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ12.04(s,1H),11.84(s,1H),8.48(s,1H),8.17(s,1H),7.86–7.71(m,2H),7.61( t,J=7.8Hz,1H),7.53–7.46(m,1H),7.41(d,J=2.4Hz,1H),2.93(d,J=7.4Hz,2H),1.28(t,J=7.4Hz,3H).
[0377] Compound 2: 4-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
[0378]
[0379] According to step 2 in general synthetic procedure I, a white solid compound 4-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (23 mg, 18%) was obtained from 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-1,2,4-triazol-3-one and intermediate A2. Mass (m / z): 351.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ12.05(s,1H),11.81(s,1H),8.48(s,1H),8.17(s,1H),7.83(t,J=1.8Hz,1H),7.80–7.76(m,1H),7. 62(t,J=7.8Hz,1H),7.49(d,J=7.8Hz,1H),7.33(d,J=1.4Hz,1H),2.27–2.16(m,1H),0.90–0.79(m,2H),0.69–0.58(m,2H).
[0380] Example 3: 1-(3-{4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl}phenyl)imidazolidin-2-one
[0381]
[0382] According to the general synthetic procedure I, a white solid compound 1-(3-{4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl}phenyl)imidazolidin-2-one (90 mg, 34%) was obtained from 1-(3-bromophenyl)imidazolidin-2-one and intermediate A1. Mass (m / z): 341.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ13.26(s,1H),8.11(s,1H),7.73(s,1H),7.50(dd,J=19.2,7.8Hz,2H),7.34(s ,1H),7.12(d,J=7.2Hz,1H),4.01(s,2H),3.67(S,2H),3.03(q,J=7.4Hz,2H),1.35(t,J=7.4Hz,3H).
[0383] Compound 4: 1-(3-{4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-yl}phenyl)imidazolidin-2-one
[0384]
[0385] According to step 2 of general synthetic procedure I, 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imidazolidin-2-one and intermediate A2 were used to obtain a white solid compound 1-(3-{4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-yl}phenyl)imidazolidin-2-one (23 mg, 11%). Mass (m / z): 352.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δ13.14(s,1H),8.09(s,1H),7.76(s,1H),7.48(s,2H),7.18(d,J=28.0H z, 2H), 4.01 (s, 2H), 3.66 (s, 2H), 2.22 (s, 1H), 1.00 (d, J = 7.6Hz, 2H), 0.70 (d, J = 4.2Hz, 2H).
[0386] Compound 5: 1-(4-{4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-yl}-1,3-thiazol-2-yl)-1,3-diaxinan-2-one
[0387]
[0388] Step 1. Preparation of 1-(4-bromo-1,3-thiazol-2-yl)-1,3-diazinane-2-one: To a solution of 4-bromo-1,3-thiazol-2-amine (2 g, 11.2 mmol) in DMF (30 mL) was added 1-chloro-3-isocyanatopropane (2.68 g, 22.4 mmol) and DIEA (4.34 g, 33.6 mmol). The reaction mixture was stirred at 120 ° C and N2 for 16 h. The solution was concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1:1) to give a yellow solid (1.4 g, 44%). Mass (m / z): 262.0 [M+H] + .
[0389] Step 2. According to the general synthetic procedure I, from 1-(4-bromo-1,3-thiazol-2-yl)-1,3-diazinane-2-one and intermediate A2, a yellow solid compound 1-(4-{4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-yl}-1,3-thiazol-2-yl)-1,3-diazinane-2-one (16 mg, 4.7%) was obtained. Mass (m / z): 374.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ11.74(s,1H),8.56(s,1H),7.45(d,J=6.9Hz,2H),7.26(s,1H),4.11(t, J=5.8Hz,2H),3.25(s,2H),2.22(s,1H),2.00(s,2H),0.90–0.80(m,2H),0.64(t,J=4.6Hz,2H).
[0390] Compound 6: 1-(6-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)imidazolidin-2-one
[0391]
[0392] Step 1. Preparation of 1-(6-bromopyridin-2-yl)-3-(2-chloroethyl)urea: To a solution of 6-bromopyridin-2-amine (3 g, 0.017 mol) in THF (60 mL), 1-chloro-2-isocyanatoethane (2.19 g, 0.02 mol) was added. The reaction mixture was stirred at 75 ° C. under N2 for 18 h. The reaction mixture was filtered. The filter cake was dried to give a white solid product 1-(6-bromopyridin-2-yl)-3-(2-chloroethyl)urea (3.87 g, 80%). Mass (m / z): 279.8 [M+H] + .
[0393] Step 2. Preparation of 1-(6-bromopyridin-2-yl)imidazolidin-2-one: To a solution of 1-(6-bromopyridin-2-yl)-3-(2-chloroethyl)urea (3.87 g, 0.014 mol) in THF (60 mL) was added NaH (60% in oil, 0.83 g, 0.021 mol) at 0°C. The reaction mixture was stirred at room temperature under N2 for 1 h. After the reaction was completed, the reaction mixture was added to ice water (100 mL) and then extracted with EA (150 mL x 3). The combined organic layers were washed with brine (100 mL x 2) and then dried over anhydrous Na2SO4. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give the product 1-(6-bromopyridin-2-yl)imidazolidin-2-one (3.47 g, 82%) as a white solid. Mass (m / z): 243.8 [M+H] + .
[0394] Step 3. According to the general synthetic procedure I, 1-(6-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)imidazolidin-2-one (11 mg, 8%) was obtained as a white solid compound from 1-(6-bromopyridin-2-yl)imidazolidin-2-one and intermediate A2. Mass (m / z): 354.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ11.80(s,1H),8.32(s,1H),8.19(d,J=8.4Hz,1H),7.85–7.77(m,1H),7.30(d,J=7.2Hz,2H),7.24 (s,1H),4.09–4.00(m,2H),3.45–3.38(m,2H),2.22(d,J=4.8Hz,1H),0.86(dt,J=5.8,4.2Hz,2H),0.65(q,J=5.8Hz,2H).
[0395] Compound 7: 1-(4-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one
[0396]
[0397] Step 1. 1-(4-bromo-5-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one: To a solution of 4-bromo-5-methyl-1,3-thiazol-2-amine (1 g, 5.18 mmol) and DIEA (2 g, 15.53 mmol) in DMF (2 mL), 1-chloro-3-isocyanatopropane (681 mg, 5.69 mmol) was added. The reaction mixture was stirred at 120 ° C under N2 for 18 h. The solution was concentrated under reduced pressure. The residue was purified by column chromatography (EA / PE=1:3) to give the desired brown solid product (600 mg, yield: 39%). Mass (m / z): 276.0 [M+H] + .
[0398] Step 2. According to the general synthetic procedure I, from 1-(4-bromo-5-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one and intermediate A2, a yellow solid compound 1-(4-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methylthiazol-2-yl)tetrahydropyrimidin-2(1H)-one (15 mg, 5%) was obtained. Mass (m / z): 388.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ11.74(d,J=2.2Hz,1H),8.09(s,1H),7.38(s,1H),7.28(d,J=1.8Hz,1H),3.96(t,J =5.8Hz,2H),3.23(s,2H),2.26–2.11(m,4H),1.96(d,J=5.8Hz,2H),0.89–0.80(m,2H),0.68–0.58(m,2H).
[0399] Compound 8: 1-(6-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)tetrahydropyrimidin-2(1H)-one
[0400]
[0401] Step 1. Preparation of 1-(6-bromopyridin-2-yl)-3-(4-chlorobutyl)urea: To a solution of 6-bromopyridin-2-amine (3 g, 0.017 mol) in THF (60 mL), 1-chloro-3-isocyanatopropane (2.48 g, 0.02 mol) and TEA (3.49 g, 0.035 mmol) were added. The reaction mixture was stirred at 75 ° C and N2 for 18 h. The reaction mixture was filtered. The filter cake was dried to give a white solid product 1-(6-bromopyridin-2-yl)-3-(4-chlorobutyl)urea (3.4 g, 70%). Mass (m / z): 293.8 [M+H] + .
[0402] Step 2. Preparation of 1-(6-bromopyridin-2-yl)tetrahydropyrimidin-2(1H)-one: To a solution of 1-(6-bromopyridin-2-yl)-3-(4-chlorobutyl)urea (3.4 g, 0.006 mol) in THF (60 mL) at 0°C, NaH (60% in oil, 0.67 g, 0.017 mol) was added. The reaction mixture was stirred at room temperature under N2 for 1 h. After the reaction was completed, the reaction mixture was added to ice water (100 mL) and then extracted with EA (100 mL x 3). The combined organic layers were washed with brine (100 mL x 2) and then dried over anhydrous Na2SO4. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give the product 1-(6-bromopyridin-2-yl)tetrahydropyrimidin-2(1H)-one (3.36 g, 94%) as a white solid. Mass (m / z): 255.9 [M+H] + .
[0403] Step 3. According to the general synthetic procedure I, 1-(6-bromopyridin-2-yl)tetrahydropyrimidin-2(1H)-one and intermediate A2 were used to obtain a white solid compound 1-(6-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)tetrahydropyrimidin-2(1H)-one (19 mg, 5%). Mass (m / z): 368.1 [M+H] + . 1 HNMR(400MHz,DMSO-d6)δ11.80(s,1H),8.30(s,1H),7.90(d,J=8.4Hz,1H),7.82–7.74(m,1H),7.32(dd,J=12.0,4.4Hz,2H),6.94(s, 1H),3.98–3.89(m,2H),3.23(t,J=4.6Hz,2H),2.26–2.18(m,1H),1.95(dd,J=11.4,5.8Hz,2H),0.89–0.81(m,2H),0.69–0.61(m,2H).
[0404] Compound 9: 1-(3-{4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl}phenyl)-1,3-diazinane-2-one
[0405]
[0406] Step 1. Preparation of 3-(3-chloropropyl)-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea: To a mixture of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.00 g, 9.13 mmol) and dichloromethane (20.0 mL) was added 1-chloro-3-isocyanatopropane (1.31 g, 10.9 mmol) at 0°C. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give a white solid product, 3-(3-chloropropyl)-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea (3.30 g, 96%). Mass (m / z): 340.9 [M+H] + .
[0407] Step 2. Preparation of 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-diazinane-2-one: To a mixture of 3-(3-chloropropyl)-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea (3.30 g, 9.74 mmol) and THF (30.0 mL) at 0°C, NaH (60% in oil, 702 mg, 29.2 mmol) was added. The reactants were stirred at 0°C for 30 min and then at 50°C for 2 h. The reaction mixture was quenched with NH4Cl solution (50 mL) and then extracted with EA (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, and concentrated under reduced pressure to give a white solid product, 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-diazinane-2-one (1.20 g, 36%). Mass (m / z): 303.0 [M+H] + .
[0408] Step 3. According to step 2 of general synthetic procedure I, 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-diazinane-2-one and intermediate A1 were used to obtain a white solid compound 1-(3-{4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl}phenyl)-1,3-diazinane-2-one (30 mg, 16%). Mass (m / z): 354.9 [M+H] + . 1H NMR (400MHz, CDCl3) δ10.23(s,1H),8.16(s,1H),7.46–7.40(m,3H),7.29(d,J=7.2Hz,1H),7.12(s,1H),5.58( s, 1H), 3.78 (s, 2H), 3.47 (d, J = 8.2Hz, 2H), 3.00 (q, J = 7.4Hz, 2H), 2.13 (d, J = 5.0Hz, 2H), 1.32 (t, J = 7.4Hz, 3H).
[0409] Compound 10: 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione
[0410]
[0411] Step 1: Preparation of tert-butyl 3-(3-bromophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate: To a solution of tert-butyl {2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-yl}carboxylate (2 g, 7.80 mmol) and (3-bromophenyl)boranediol (2.03 g, 10.14 mmol) in DCM (40 mL) was added Cu(OAc)2 (1.41 g, 7.80 mmol) and pyridine (1.85 g, 23.41 mmol). The reaction mixture was stirred at room temperature under 1 atm O2 for 16 h. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (DCM / MeOH=20:1) to give a white solid (2 g, 56%). Mass (m / z): 432.0434.0 [M+Na] + .
[0412] Step 2: Preparation of tert-butyl 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate: According to the general synthetic procedure I, tert-butyl 3-(3-bromophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate and intermediate A2 were used to obtain yellow oily compound 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate (800 mg, 78%). Mass (m / z): 522.0 [M+H] + .
[0413] Step 3: Preparation of 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione: To a solution of tert-butyl 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate (300 mg, 0.573 mmol) in DCM (5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated and the residue was purified by preparative HPLC [Gemini-C18 150x21.2 mm, 5 um, ACN-H2O (0.1% FA), 20-50] to give the product as a white solid (110 mg, 44%). Mass (m / z): 422.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ11.81(s,1H),9.37(s,1H),9.04(s,1H),8.12(s,1H),7.73–7.41(m,4H),7.33(d,J=1.6Hz,1H),3.64(d,J =12.8Hz,1H),3.46–3.39(m,2H),2.48–2.38(m,1H),2.34–2.16(m,2H),1.32–1.17(m,1H),0.91–0.79(m,2H),0.71–0.52(m,2H).
[0414] Compound 11: 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-1,3,7-triazaspiro[4.4]nonan-2-one
[0415]
[0416] Step 1: Preparation of tert-butyl 2-oxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate: To a solution of tert-butyl {2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-yl}carboxylate (500 mg, 1.95 mmol) in THF (20 mL) was added BH3-THF (1 M, 10 mL, 9.755 mmol). The reaction mixture was stirred at 65 ° C and N2 for 3 h. The reaction mixture was concentrated. H2O (20 mL) was added to the reaction mixture, and then extracted with DCM (20 mLx3). The combined organic layers were washed with brine (20 mLx2) and then dried over anhydrous Na2SO4. After filtration, the solution was concentrated under vacuum to give a white solid product (400 mg, 67%). Mass (m / z): 483.3 [2M+H]+ .
[0417] Step 2: Preparation of tert-butyl 3-(3-bromophenyl)-2-oxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate: To a solution of tert-butyl {2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-yl}carboxylate (250 mg, 0.97 mmol) and (3-bromophenyl)boranediol (588 mg, 2.92 mmol) in DCM (10 mL) was added Cu(OAc)2 (354 mg, 1.95 mmol) and pyridine (231 mg, 2.92 mmol). The reaction mixture was stirred at 25 °C and 1 atm O2 for 16 h. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (DCM / MeOH=20:1) to give a yellow solid product (60 mg, 16%). Mass (m / z): 339.9 [M-55] + .
[0418] Step 3: Preparation of tert-butyl 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2-oxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate: According to the general synthetic procedure I, tert-butyl 3-(3-bromophenyl)-2-oxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate and intermediate A2 were used to obtain tert-butyl 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2-oxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate (80 mg, 100%) as a yellow oily compound. Mass (m / z): 508.0 [M+H] + .
[0419] Step 4: Preparation of 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-1,3,7-triazaspiro[4.4]nonane-2-one: To a solution of tert-butyl 3-(3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-2-oxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate (80 mg, 0.157 mmol) in DCM (3 mL) was added TFA (0.5 mL). The reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated and the residue was purified by preparative HLPC [Gemini-C18 150x21.2 mm, 5um; ACN--H2O (0.1% FA), 18-30] to give the product as a yellow solid (3.5 mg, 5.5%). Mass (m / z): 204.6 [M / 2+H] + . 1H NMR (400MHz, DMSO-d6) δ11.76(s,1H),8.10(s,1H),7.68–7.55(m,3H),7.46–7.40(m,1H),7.31(s,1H),7.11(d,J=7.6Hz,1H),3.97(dd,J=18 .2,9.8Hz,2H),3.23(d,J=11.3Hz,3H),3.05(d,J=11.6Hz,1H),2.25–2.17(m,1H),2.11–1.98(m,2H),0.90–0.81(m,2H),0.69–0.60(m,2H).
[0420] Compound 12: 4-Chloro-N-ethyl-N-methyl-5-(3-(2-oxotetrahydropyrimidin-1(2H)-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide
[0421]
[0422] Step 1: Preparation of 1-(3-chloropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea: To a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1000 mg, 4.5644 mmol) in DCM (20 mL), prop-2-enal (654.81 mg, 5.4772 mmol) was added, the reaction solution was stirred at room temperature for 18 h, and concentrated under reduced pressure to obtain the target product as a white solid (1500 mg, 97.04%). Mass (m / z): 339 [M+H] + .
[0423] Step 2. Preparation of 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahydropyrimidin-2(1H)-one: To a solution of 3-(3-chloropropyl)-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea (1500 mg, 4.42 mmol) in THF (30 mL) at 0°C, NaH (531 mg, 13.28 mmol) was added. The reaction mixture was stirred at 0°C for 0.5 h and at 50°C for 2 h. The reaction mixture was quenched with water (50 mL) and then extracted with ethyl acetate (30 mLx3). The combined organic layers were washed with brine (30 mLx2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (EA / PE=1:1) to obtain a white solid product (350 mg, yield: 24.84%). Mass (m / z): 303 [M+H] + .
[0424] Step 3. Preparation of 5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid: To a solution of 3-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine (500 mg, 2.16 mmol) in DCM (10 mL), AlCl3 (719 mg, 5.4 mmol) was added, and the reaction solution was stirred at room temperature for 1 h. Then 2,2,2-trichloroacetyl chloride (471.31 mg, 2.592 mmol) was added. The reaction solution was stirred at room temperature for 18 h. The mixture was concentrated and the residue was purified by column chromatography (DCM / MeOH=10:1) to obtain the target product as a yellow solid (250 mg, 39.91%). Mass (m / z): 275[M+H] + .
[0425] Step 4. Preparation of 5-bromo-4-chloro-N-ethyl-N-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide: 5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (200 mg, 0.726 mmol), ethyl(methyl)amine (51 mg, 0.87 mmol), DIEA (281 mg, 2.178 mmol) and T3P (50% in EA, 1385 mg, 2.178 mmol) in EA (2 mL). The reaction mixture was stirred at 75 °C under N2 for 18 h. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH=10:1) to give the desired product (70 mg, yield: 28%) as a white solid. Mass (m / z): 316 [M+H] + .
[0426] Step 5. Preparation of 4-chloro-N-ethyl-N-methyl-5-(3-(2-oxotetrahydropyrimidin-1(2H)-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide: To a mixture of 5-bromo-4-chloro-N-ethyl-N-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (60 mg, 0.189 mmol), 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-diazinane-2-one (85 mg, 0.284 mmol) and K2CO3 (52 mg, 0.379 mmol) in dioxane / H2O (10:1, 1 mL) under N2 was added Pd(dppf)Cl2 (15 mg, 0.0189 mmol). The reaction mixture was stirred at 90°C for 18 h. The reaction mixture was filtered and concentrated. The residue was purified by preparative HPLC [Gemini-C18 150x21.2 mm, 5um; ACN-H2O (0.1% FA), 10-40] to give the desired product as a white solid (2.5 mg, yield: 3%). Mass (m / z): 412 [M+H] + . 1 HNMR(400MHz, CDCl3)δ7.78(s,2H),7.58(s,1H),7.49(dd,J=21.8,14.2Hz,4H),7.17(s,1H),3.78(s,2H),3.6 4(d,J=7.0Hz,1H),3.51(s,2H),3.31(s,1H),3.12(s,1H),2.92(s,1H),2.16(s,2H),1.25(s,2H),1.10(s,2H).
[0427] Compound 13: 3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(2-oxotetrahydropyrimidin-1(2H)-yl)benzonitrile
[0428]
[0429] Step 1: Preparation of 3-bromo-5-isocyanatobenzonitrile: TEA (0.5 g, 5.08 mmol) and BTC (1.51 g, 5.08 mmol) were added to a solution of 3-amino-5-bromobenzonitrile (1 g, 5.08 mmol) in DCE (20 mL). The reaction mixture was stirred at 85 ° C. under N2 for 16 h. The solution was concentrated under reduced pressure to give a yellow solid product, 3-bromo-5-isocyanatobenzonitrile (1.5 g, 80%).
[0430] Step 2. Preparation of 1-(3-bromo-5-cyanophenyl)-3-(3-chloropropyl)urea: To a solution of 3-bromo-5-isocyanatobenzonitrile (1.5 g, 6.76 mmol) in DCM (30 mL), 3-chloropropane-1-amine hydrochloride (580 mg, 5.63 mmol) and DIEA (1.15 g, 11.26 mmol) were added. The reaction mixture was stirred at room temperature under N2 for 16 h. The solution was concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1:1) to give a yellow oily product 1-(3-bromo-5-cyanophenyl)-3-(3-chloropropyl)urea (1.39 g, 98%). Mass (m / z): 317.9 [M+H] + .
[0431] Step 3. Preparation of 3-bromo-5-(2-oxotetrahydropyrimidin-1(2H)-yl)benzonitrile: To a solution of 1-(3-bromo-5-cyanophenyl)-3-(3-chloropropyl)urea (150 mg, 0.48 mmol) in DCM (10 mL) was added TEA (144 mg, 1.44 mmol) and BTC (65 mg, 0.24 mmol). The reaction mixture was stirred at room temperature for 3 h under N2. After the reaction was completed, H2O (50 mL) was added to the reaction mixture, which was then extracted with DCM (30 mLx3). The combined organic layers were washed with brine (50 mLx3) and then dried over anhydrous Na2SO4. After filtration, the solution was concentrated in vacuo. The residue was purified by flash chromatography (PE / EtOAc=1:1) to give a yellow solid product, 3-bromo-5-(2-oxotetrahydropyrimidin-1(2H)-yl)benzonitrile (60 mg, 48%). Mass (m / z): 282.0 [M+H] + .
[0432] Step 4. Preparation of 3-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(2-oxotetrahydropyrimidin-1(2H)-yl)benzonitrile: According to the general synthetic procedure I, 3-bromo-5-(2-oxotetrahydropyrimidin-1(2H)-yl)benzonitrile and Intermediate A2 were used to obtain a white solid product (5 mg, 6.4%). Mass (m / z): 392.0 [M+H] + . 1 HNMR(400MHz,CD3OD)δ8.13(s,1H),7.77(dd,J=7.8,1.6Hz,2H),7.67(s,1H),7.18(s,1H),3.82(s,2H),3.4 0(t,J=5.8Hz,2H),2.25(t,1H),2.17–2.09(m,2H),0.91(dd,J=8.2,1.8Hz,2H),0.65(dd,J=5.2,1.6Hz,2H).
[0433] Compound 14: 1-(5-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(methylsulfonyl)phenyl)tetrahydropyrimidin-2(1H)-one
[0434]
[0435] Step 1.N 1 Preparation of -(5-bromo-2-(methylsulfonyl)phenyl)propane-1,3-diamine: A mixture of 4-bromo-2-fluoro-1-methylsulfonylbenzene (1000 mg, 3.95 mmol), 1,3-diaminopropane-1,2,3-tri(ylium) (577 mg, 7.90 mmol) and K2CO3 (1092 mg, 7.90 mmol) in DMSO (10 mL). The reaction mixture was stirred at 80 ° C for 18 h. The reactants were filtered and concentrated. The residue was flash purified with a mixture of MeOH:DCM (1:10) to give a brown solid product (600 mg, yield: 46%). Mass (m / z): 307 [M+H] + .
[0436] Step 2. Preparation of 1-(5-bromo-2-(methylsulfonyl)phenyl)tetrahydropyrimidin-2(1H)-one: To a solution of N-(3-aminopropyl)-5-bromo-2-methylsulfonylaniline (600 mg, 1.30 mmol) and DIEA (503 mg, 3.90 mmol) in DCM (20 mL) was added dropwise a solution of BTC (405 mg, 1.36 mmol) in DCM (5 mL) at 0°C. The reaction mixture was stirred at room temperature under N2 for 18 h. The solution was concentrated under reduced pressure. The residue was purified by column chromatography (EA / PE=1:1) to give the desired brown solid product (500 mg, yield: 72%). Mass (m / z): 333 [M+H] + .
[0437] Step 3. Preparation of 1-(5-(4-chloro-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(methylsulfonyl)phenyl)tetrahydropyrimidin-2(1H)-one: According to the general synthetic procedure I, the desired white solid product (10 mg, yield: 5.8%) was obtained from 1-(5-bromo-2-(methylsulfonyl)phenyl)tetrahydropyrimidin-2(1H)-one and intermediate A2. Mass (m / z): 445.1 [M+H] + . 1H NMR (400MHz, CDCl3) δ11.83 (s, 1H), 8.14 (s, 1H), 7.98 (d, J = 8.2Hz, 1H), 7.6 8(dd,J=8.2,1.8Hz,1H),7.62(d,J=1.8Hz,1H),7.31(d,J=1.6Hz,1H),6.77( s,1H),3.62–3.53(m,1H),3.48(dd,J=10.8,5.2Hz,1H),3.25–3.16(m,5H), 2.21–2.12(m,1H),2.01–1.87(m,2H),0.85–0.75(m,2H),0.65–0.55(m,2H).
[0438] Example 2: Biological Data
[0439] HPK1 enzyme assay
[0440] The compound was dissolved in 100% DMSO at a concentration of 10mM. HPK1 protein was purchased from Signal Chem (M23-11G-10). 2X HPK1 protein was added to the test plate containing the test compound at 2.5μL per well, centrifuged at 1500rpm for 1min, and then incubated at 25°C for 60min. MBP protein was purchased from Signal Chem (M42-51N) and ATP was purchased from Promega (V9102). A mixture of 2XMBP (0.2ug / ul) and ATP (20μM) was added to each well, centrifuged at 1500rpm for 1min, and incubated at 25°C for 60min. Then 5μL of Promega's ADP-Glo (V9102) was added to the test plate to deplete unconsumed ATP within 60min. Then centrifuged at 1500rpm for 1min and incubated at 25°C for 60min. Finally, 10 μL of kinase detection reagent (V9102) from Promega was added to the test plate to convert ADP into ATP, centrifuged at 1500 rpm for 1 min, and incubated at 25°C for 40 min. After incubation for 40 min, the fluorescence was measured. The IC value of the compound was calculated based on the results. 50 Value. IC 50 The results are shown in Table 2 below.
[0441] FLT3-ITD enzyme assay
[0442] The compound was dissolved in 100% DMSO at a concentration of 10 mM. FLT3-ITD protein was purchased from Invitrogen (PV6191). 2.5X FLT3-ITD protein was added to the test plate containing the test compound at 10 μL per well, centrifuged at 1000 rpm for 1 min, and then incubated at 25°C for 10 min. Peptide 2 was purchased from GLBiochem (112394) and ATP was purchased from Promega (V9102). A mixture of 15 μL 1.67X peptide 2 (final concentration of 3 μM) and ATP (final concentration of 97.2 μM) was added to each well, centrifuged at 1000 rpm for 1 min, and then incubated at 25°C for 40 min. Then, 30 μL of stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 0.2% Coating Reagent 3, 50 mM EDTA) was added to the test plate, centrifuged at 1000 rpm for 1 min, and the product was measured. The IC value of the compound was calculated based on the results. 50 Value. IC 50 The results are shown in Table 2 below.
[0443] Aurora kinase A enzyme assay
[0444] The compounds were dissolved in 100% DMSO at a concentration of 10 mM. Aurora kinase A protein was purchased from Carna (05-101). 2.5X Aurora kinase A protein was added to the test plate containing the test compound at 10 μL per well, centrifuged at 1000 rpm for 1 min, and then incubated at 25°C for 10 min. Peptide 21 was purchased from GL Biochem (116370) and ATP was purchased from Promega (V9102). A mixture of 15 μL of 1.67X peptide 21 (final concentration of 3 μM) and ATP (final concentration of 14.58 μM) was added to each well, centrifuged at 1000 rpm for 1 min, and then incubated at 25°C for 40 min. Then, 30 μL of stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 0.2% Coating Reagent 3, 50 mM EDTA) was added to the test plate, centrifuged at 1000 rpm for 1 min, and the product was measured. The IC value of the compound was calculated based on the results. 50 Value. IC 50 The results are shown in Table 2 below.
[0445] Table 2. Enzyme inhibition test results of compounds
[0446]
[0447] The present disclosure provides only exemplary embodiments. Those skilled in the art will readily recognize from the disclosure herein and the claims that various changes, modifications and variations may be made thereto without departing from the spirit and scope of the present disclosure as defined in the appended claims.
Claims
1. Compounds of formula I: Its tautomer, the deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the aforementioned compound, wherein: (i)R 1 and R 2 independently selected from the group consisting of linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, linear alkenyl, branched alkenyl, cycloalkenyl, linear heteroalkenyl, branched heteroalkenyl, heteroalkenyl, linear alkynyl, branched alkynyl, cycloalkynyl, CO2R x 、C(O)NR x R y 、C(O)R x OR y 、C(O)R w N(R x R y )2、OC(O)R w NR x R y 、S(O)R y and SO2R y ; (ii) R 3 Selected from: hydrogen, halogen groups, OR x , SR x 、NHR x 、N(R x 2. CHR x and C(R x )2; (iii) R 4 Selected from: hydrogen, straight chain alkyl, branched chain alkyl, cycloalkyl, heterocyclic group, C(O)R y 、CO2R y 、C(O)R w OR y 、C(O)R w N(R x R y )2、OC(O)R w NR x R y , R w N(R x R y 2. R w OR x , R z R'、S(O)R y and SO2R y ; (iv) R x and R y R is independently selected from the group consisting of hydrogen, linear alkyl, branched alkyl, cycloalkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl; or x and R y are linked to each other to form an optionally substituted heterocycloalkyl group; (v)R w is absent or is selected from the group consisting of: straight chain alkyl, branched chain alkyl, cycloalkyl, carbocyclyl, heterocyclyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, straight chain heteroalkenyl, and branched chain heteroalkenyl; (vi)R z Not present or selected from: linear alkyl, branched alkyl and cycloalkyl; (vii) R' is selected from the group consisting of optionally substituted heteroaryl and optionally substituted heterocycloalkyl; (viii) Ring A is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and (ix) Ring B is selected from: (x) wherein each R" is independently selected from: hydrogen, linear alkyl, branched alkyl and cycloalkyl; or two R" combine to form a cycloalkyl spiro ring or a heterocycloalkyl spiro ring; wherein the straight chain alkyl, branched chain alkyl, cycloalkyl, straight chain alkenyl, branched chain alkenyl, cycloalkenyl, carbocyclyl, branched chain heteroalkenyl, branched chain heteroalkenyl, straight chain alkynyl, branched chain alkynyl, cycloalkynyl, heterocyclyl, aryl and heteroaryl are optionally substituted by at least one group selected from the following groups: Halogen groups, Hydroxyl, Thiols, Amino, Cyano, -OC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl, -C(O)OC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl, -NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl, -N(C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl)2, -NHC(O)C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl, -C(O)NHC1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl, -NH aryl, -N(aryl)2, -NHC(O)aryl, -C(O)NHaryl, -NH heteroaryl, -N(heteroaryl)2, -NHC(O)heteroaryl, -C(O)NHheteroaryl, C1-C6 straight chain alkyl, branched chain alkyl and cycloalkyl, C2-C6 straight-chain alkenyl, branched-chain alkenyl and cycloalkenyl, C1-C6 straight chain hydroxyalkyl, branched chain hydroxyalkyl and cyclic hydroxyalkyl, C1-C6 straight-chain aminoalkyl, branched-chain aminoalkyl and cyclic aminoalkyl, C1-C6 straight chain alkoxy, branched chain alkoxy and cycloalkoxy, C1-C6 straight chain sulfanyl, branched chain sulfanyl and cyclic sulfanyl, C1-C6 straight chain haloalkyl, branched chain haloalkyl and cyclic haloalkyl, C1-C6 straight chain halogenated aminoalkyl, branched chain halogenated aminoalkyl and cyclic halogenated aminoalkyl, C1-C6 straight chain halosulfanyl, branched chain halosulfanyl and cyclic halosulfanyl, C1-C6 straight chain halogenated oxyalkyl, branched chain halogenated oxyalkyl and cyclic halogenated oxyalkyl, benzyloxy, benzylamino and benzylthio, 3-6 membered heterocycloalkenyl, 3-6 membered heterocyclyl, 3-6 membered spirocycloalkyl, 3-6 membered spiroheterocyclyl, and 5-membered heteroaryl and 6-membered heteroaryl, which are optionally substituted with 0, 1 or 2 C1-C6 alkyl groups selected from the group consisting of linear alkyl, branched alkyl and cycloalkyl.
2. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein R 1 and R 2 are independently selected from: hydrogen, straight chain alkyl, branched chain alkyl and cycloalkyl, and R 4 is a halogen group.
3. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt according to claim 1 or 2, wherein R 1 Selected from: C1-C6 straight chain alkyl, C1-C6 branched chain alkyl and C1-C6 cycloalkyl.
4. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 3, wherein R 1 Selected from: methyl, ethyl, cyclopropyl and cyclobutyl.
5. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein R 1 It is a heterocyclic group.
6. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein R 1 Selected from: straight chain alkynyl, branched chain alkynyl and cycloalkynyl.
7. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 6, wherein the straight chain alkynyl, branched chain alkynyl and cycloalkynyl are substituted with at least one group selected from the group consisting of a C1-C6 straight chain alkyl, a C1-C6 branched chain alkyl, a C1-C6 cycloalkyl, a C1-C6 straight chain aminoalkyl, a C1-C6 branched chain aminoalkyl, a C1-C6 cycloaminoalkyl, a 3-6 membered heterocyclyl, a 5 membered heteroaryl and a 6 membered heteroaryl.
8. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1 to 7, wherein R 2 It's hydrogen.
9. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1 to 7, wherein R 2 Selected from: straight chain alkyl, branched chain alkyl and cycloalkyl.
10. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 9, wherein R 2 Selected from: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and cyclobutyl.
11. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1 to 3, wherein R 3 is a halogen group.
12. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 11, wherein R 3 It's fluorine.
13. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 11, wherein R 3 It's chlorine.
14. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt according to any one of claims 1 to 13, wherein ring A is selected from aryl.
15. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 14, wherein ring A is phenyl.
16. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 14, wherein ring A is selected from an aryl group, and the aryl group is substituted with a halogen group.
17. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 14, wherein ring A is selected from an aryl group, and the aryl group is substituted with a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group and a C1-C6 cycloalkyl group.
18. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1 to 13, wherein ring A is selected from heteroaryl.
19. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 18, wherein ring A is selected from a heteroaryl group, and the heteroaryl group is substituted with a halogen group.
20. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 18, wherein ring A is selected from heteroaryl, and the heteroaryl is substituted with C1-C6 straight chain alkyl, C1-C6 branched chain alkyl and C1-C6 cycloalkyl.
21. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 18, wherein Ring A is selected from a 6-membered heteroaryl group.
22. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 21, wherein ring A is selected from a 6-membered heteroaryl group, and the 6-membered heteroaryl group is substituted with a halogen group.
23. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 21, wherein ring A is selected from a 6-membered heteroaryl group, and the 6-membered heteroaryl group is substituted with a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group and a C1-C6 cycloalkyl group.
24. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 23, wherein ring A is a pyridine ring.
25. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 23, wherein Ring A is a pyrimidine ring.
26. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 18, wherein ring A is selected from a 5-membered heteroaryl group.
27. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 26, wherein ring A is selected from a 5-membered heteroaryl group, and the 5-membered heteroaryl group is substituted with a halogen group.
28. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 26, wherein ring A is selected from a 5-membered heteroaryl group, and the 5-membered heteroaryl group is substituted with a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group and a C1-C6 cycloalkyl group.
29. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 28, wherein ring A is a thiazole ring.
30. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein Ring B is 31. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein Ring B is 32. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein Ring B is 33. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein Ring B is 34. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of claim 1, wherein Ring B is 35. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1 to 34, wherein R 4 It's hydrogen.
36. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1 to 34, wherein R 4 Selected from: straight chain alkyl, branched chain alkyl and cycloalkyl.
37. The compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1 to 34, wherein R 4 Selected from: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and cyclobutyl.
38. A compound selected from the group consisting of: Its tautomer, the deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the aforementioned compound.
39. A pharmaceutical composition comprising the compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1-38, and at least one pharmaceutically acceptable carrier.
40. A method of treating or ameliorating a disease, disorder or condition mediated by protein kinase inhibition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, tautomer, deuterated derivative or pharmaceutically acceptable salt of any one of claims 1-38 or a pharmaceutical composition of claim 39.
41. The method of claim 40, wherein the protein kinase is selected from the group consisting of: hematopoietic progenitor kinase 1 (HPK1), Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinase A.
42. A method of reducing protein kinase activity in a disease, disorder or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound, tautomer, deuterated derivative and / or pharmaceutically acceptable salt of any one of claims 1-38 or a pharmaceutical composition of claim 39.
43. The method of claim 40 or 42, wherein the disease, disorder or condition is selected from a protein kinase-related disease.
44. The method of claim 43, wherein the protein kinase-related disease is cancer.
45. The method of claim 44, wherein the cancer is a solid tumor.
46. The method of claim 45, wherein the solid tumor is selected from the group consisting of brain cancer, breast cancer, respiratory and / or lung cancer, reproductive organ cancer, bone cancer, digestive tract cancer, urethral cancer, eye cancer, liver cancer, skin cancer, head and neck cancer, anal cancer, nervous system cancer, thyroid cancer, and parathyroid cancer.
47. The method of claim 44, wherein the cancer is a hematological cancer.
48. The method of claim 47, wherein the blood cancer is selected from the group consisting of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and myelodysplastic syndrome (MDS).
49. The method of claim 44, wherein the cancer is selected from: oral (e.g., buccal cavity, lip, tongue, mouth, pharynx) epidermoid carcinoma; cardiac cancer, such as sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; Lung cancer, such as bronchial cancer (squamous cell or epidermal cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatosis, hamartoma, mesothelioma; gastrointestinal cancer, such as esophagus (squamous cell carcinoma, laryngeal carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vasodilatory peptide tumor), small intestine or small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine or large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyosarcoma), colon, colorectum, colorectum, rectum; genitourinary tract cancer, including kidney (adenocarcinoma, Wilms' tumor (Nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma); liver cancers, such as hepatoma (hepatocellular carcinoma), bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary tract cancer; bone cancers, such as osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor; Nervous system cancers, including skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningosarcomas, gliomatosis), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealoma), glioblastoma multiforme, oligodendrogliomas, schwannomas, retinoblastomas, congenital tumors), spinal cord neurofibromas, meningiomas, gliomas, sarcomas); gynecological cancers, including uterus (endometrial cancer), cervix (cervical cancer, preneoplastic cervical dysplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), ovarian granulosa-follicular cell tumors, ovarian Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, ovarian fibrosarcoma, fibrosarcoma, melanoma), cancers of the blood, such as malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, keratoacanthoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; cancers of the thyroid, such as papillary thyroid cancer, follicular thyroid cancer; medullary thyroid cancer, anaplastic thyroid cancer, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and cancers of the adrenal gland, such as neuroblastoma.
50. The method of claim 40 or 42, further comprising administering to the subject an existing standard of care or an FDA-approved therapy.
51. The method of claim 40 or 42, further comprising administering one or more separate pharmaceutical agents to the subject.
52. The method of claim 51, wherein the separate agent is selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, and an adjuvant therapeutic agent.
Citation Information
Patent Citations
Method of simplifying line selection in a telecommunication exchange in which the lines can be seized from this exchange as well as from a remote exchange
EP0005687A1
Treatment of damaged bone marrow and dosage units therefor
US4938949A
Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1
Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014124418A1
Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014151142A1
